Biophysical, cellular, and animal models of dystrophin missense mutations by Talsness, Dana
  
 
 
 
 
Biophysical, Cellular, and Animal Models of  
Dystrophin Missense Mutations  
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL 
OF THE UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
Dana Marie Talsness 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF  
 DOCTOR OF PHILOSOPHY 
 
 
 
Advisor, James M. Ervasti 
 
 
 
 
December, 2014 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Dana Marie Talsness, 2014 
 
  i 
Acknowledgements 
 
First I would like to thank my graduate advisor, Jim Ervasti.  He took me into his 
lab when I was an orphaned graduate student, and he has mentored and 
supported me ever since.  I will forever be grateful to him for teaching me how to 
be a scientist. 
 
I would also like to thank all of the members of the Ervasti laboratory throughout 
my years here: Ben Perrin, Chris Chamberlain, Joe Belanto, Davin Henderson, 
Michelle Jaeger, Jackie McCourt, Ali O’Rourke, J.T. Olthoff, Tung Nguyen, 
Xiaobai Patrinostro, Chris Scherber, and Paul Chatterton.  These people have 
made it a pleasure to come into work everyday, and they have all contributed 
hands-on effort to my projects or helpful conversations about science.   
 
Dawn Lowe is a long time collaborator with the Ervasti lab and I would like to 
thank her for her help with the eccentric contraction protocol and all of her 
muscle physiology knowledge.   
 
Thank you to my committee, Mary Porter, Harry Orr, David Largaespada, and 
Lihsia Chen, for their support of my graduate career throughout the years. 
 
I need to thank our program administrator, Sue Knoblauch.  If it were not for her, 
no graduate student would ever sign up for classes on time, have a student 
seminar, pass their credit for student seminar, or even be recruited to the 
program in the first place.   
 
I would like to thank all of the graduate students in my year: Joe Belanto, Keli 
Holzapfel, Chris Braden, Frazer Heinis, Brent Rivard, Spencer Lubben, Jung 
Kim, Adrienne Watson, and Nick Baltes.  We formed a special bond at Itasca, 
and their friendship and support ever since has helped me to get through grad 
school.  
 
I would have never made it to grad school in the first place if it were not for my 
parents, Andy and Ruth Strandjord.  I would like to thank them for all of their 
emotional, spiritual, and physical support throughout the years.  My parents, 
along with my sisters Laurie and Kirsten, have been my foundation in life. 
 
Finally I would like to thank my husband, Jeff Talsness.  I am so lucky to have 
found someone who supports me in my higher education endeavors, even 
though it means nights spent staring at my computer and weekends spent in the 
lab.  Thank you for all of your encouragement and your calm voice of reason.   
  ii 
Dedication 
 
 
 
 
 
 
 
 
 
 
 
This dissertation is dedicated to my grandparents, Rolf and Henrietta Strandjord 
and Robert and Margaret Boyd. 
  iii 
Abstract 
The 427kDa protein dystrophin is expressed in skeletal muscle where it localizes 
to the costamere and physically links the interior of muscle fibers to the 
extracellular matrix.  Mutations in the DMD gene encoding dystrophin lead to a  
severe muscular dystrophy known as Duchenne (DMD) or a mild form known as 
Becker (BMD).  Currently, there is no cure for DMD or BMD, but there are 
several therapies being investigated that target specific types of mutations found 
in the DMD gene.  Nonsense mutations almost always lead to a complete lack of 
dystrophin protein, with stop codon read-through drugs being studied for 
personalized treatments.  Out-of-frame deletions and insertions also cause 
nearly a complete lack of dystrophin, for which exon-skipping is currently being 
investigated.  Missense mutations in dystrophin, however, cause a wide range of 
phenotypic severity in patients, the molecular and cellular consequences of such 
mutations are not well understood, and there are no therapies currently targeting 
this genotype.  Here, we report on three separate model systems of missense 
mutations in dystrophin: an in vitro biochemical model, a myoblast cell culture 
model, and an in vivo animal model.  Together, they provide evidence that 
different missense mutations cause variable degrees of thermal instability, which 
leads to proportionally decreased dystrophin expression, and subsequently 
causes dystrophic phenotypes.  In addition, our initial studies of small molecule 
treatments show that it is possible to increase the levels of mutant dystrophin, 
and may lead to personalized therapeutics for patients with missense mutations. 
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Introduction 
 
 
  
  2 
Muscle and the Dystrophin-Glycoprotein Complex 
 Skeletal muscle is composed of a bundle of fascicles each surrounded by 
the perimysium connective tissue, and each fascicle is composed of a bundle of 
muscle fibers, or myofibers.  Myofibers are the cellular unit, each surrounded by 
a plasma membrane, or sarcolemma.  An individual myofiber is formed during 
development by the fusion of several embryonic myoblast cells, giving it an 
elongated shape with multiple nuclei.  When a myofiber is viewed 
microscopically, it appears striated with alternating light and dark bands known 
as I and A bands respectively due to the protein patterns of the bundled 
myofibrils within a myofiber.  The dark A bands are composed mostly of myosin 
and the light I bands of actin filaments.  In the center of each I band is a thin dark 
Z line to which the actin filaments are anchored.  Between two Z discs, the actin 
and myosin interact to form a functional contractile unit know as the sarcomere.   
 Localized at the Z disc and extending from the bundle of myofibrils out to 
the sarcolemma is a cluster of proteins known as the costamere (Ervasti, 2003), 
which couples the force generated by the sarcomeres to the plasma membrane 
of the cell, as a highly specialized type of focal adhesion.  A sub-complex within 
the costamere, known as the dystrophin-glycoprotein complex (DGC), physically 
links the cytoplasmic actin to the extracellular matrix (Figure 1.1).  The DGC was 
first discovered when it was found that the protein of interest, dystrophin, could 
be enriched by wheat germ agglutinin chromatography, and then the complex 
further purified into 10 constitutive proteins (Ervasti et al., 1990). The major 
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components of the DGC are dystrophin, α- and β-dystroglycan, sarcospan, the 
sarcoglycans, dystrobrevin, and the syntrophins (Figure 1.1) (Ervasti, 2007). 
 It is clear that the dystrophin glycoprotein complex is necessary for 
myofiber integrity given that mutations in many of the subunits cause various 
forms of muscular dystrophy (Rahimov and Kunkel, 2013).  Mutations that lead to 
a loss of function in dystrophin cause Duchenne and Becker muscular dystrophy, 
which is the major focus of this thesis.  α- and β-dystroglycan are encoded by a 
single gene and then post-translationally cleaved.  Mutations in the 
glycosyltransferases that glycosylate α-dystroglycan lead to several forms of 
congenital muscular dystrophy (Michele et al., 2002).  Additionally, mutations in 
the dystroglycan gene itself lead to limb girdle muscular dystrophy (Hara et al., 
2011).  Autosomal recessive mutations that occur in any of the 4 sarcoglycans 
also leads to limb girdle muscular dystrophy (Ozawa et al., 2005).  Knock-out of 
α-dystrobrevin has been shown to cause progressive myopathy (Grady et al., 
1999).  Together these lines of evidence show that an intact DGC is essential to 
muscle fiber integrity and tissue function.   
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Dystrophin 
DNA 
 The gene encoding dystrophin, known as DMD, is located on the short 
arm of the X chromosome and is the largest in the human genome at 2.4Mb of 
DNA (Koenig et al., 1987).  It is comprised of 79 exons (Roberts et al., 1993), far 
above the genomic average of 8.8 exons per gene (Sakharkar et al., 2004).  The 
introns for dystrophin average over 30kb, again above the genomic average with 
<10% of all introns being more than 11kb in length.  There are also several 
alternate promoter regions which express dystrophin in non-muscle tissues of the 
body including brain (Nudel et al., 1989; Górecki et al., 1992), retina (Pillers et 
al., 1993), peripheral nerves (Byers et al., 1993), liver, lung, and kidney (Bar et 
al., 1990).  The high number of exons, the large length of the introns, and the 
multiple promoters all contribute to the enormity of the DMD locus. 
RNA 
 Due to the length of the DMD gene, transcription and splicing takes up to 
16 hours in the cell (Tennyson et al., 1995).  This study was in fact one of the first 
lines of evidence that splicing in vertebrates occurs co-transcriptionally. All of the 
exons together with the 5’ and 3’ UTRs generate a 14kb dystrophin transcript.  
The dystrophin mRNA has a half life of 15.6 ± 2.8 hours, and at steady-state 
levels there are approximately 5-10 copies per nucleus in adult muscle tissue, 
making dystrophin a low-copy transcript (Tennyson et al., 1996).  In addition to 
the dystrophin mRNA, the DMD locus also encodes several long non-coding 
  5 
RNAs (lncRNA) within the intronic regions (Bovolenta et al., 2012).  These 
lncRNAs are localized to the nucleus and were shown to specifically target the 
promoter regions for the DMD gene itself and to down-regulate transcription.  In 
this way, it appears that the gene encoding dystrophin has its own negative 
feedback, ensuring proper expression levels.   
Protein 
 Dystrophin protein is a 427kDa structural protein composed of an N-
terminal globular domain, a long central rod region, a cysteine-rich globular 
domain, and an intrinsically disordered C-terminal tail (CT) (Figure 1.2) (Koenig 
et al., 1988).  The central rod region is composed of 24 spectrin-like repeats 
(SLR), each a triple helical structure (Muthu et al., 2012), with four hinge domains 
interspersed, allowing for some flexibility of the protein (Koenig and Kunkel, 
1990).  The N-terminus (NT) (crystalized in Norwood et al. 2000) is composed of 
tandem calponin homology (CH) domains, which together bind filamentous actin 
and are designated actin binding domain 1 (ABD1).  A second actin-binding 
domain (ABD2) was discovered in the central rod region (SLR11-17), suggesting 
dystrophin binds laterally along filamentous actin (Rybakova et al., 1996).  
 The structure of the cysteine rich (CR) region can be subdivided into 
several common motifs:  There is a WW domain, so named for two conserved 
tryptophan residues, which recognizes proline-rich regions of binding-partner 
proteins (Bork and Sudol, 1994).  Then, there are two EF-hand domains, a 
structural element found in calcium binding proteins (Koenig et al., 1988). And 
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finally there is a ZZ domain, where cysteine residues coordinate Zn2+ ions in a 
conserved zinc finger motif (Ponting et al., 1996).  Together the WW, EF-hand, 
and ZZ motifs form a region that binds to β–dystroglycan (Hnia et al., 2007), and 
so the CR domain is also referred to as the dystroglycan-binding domain (DgBD).  
The specific residues that interact between dystrophin and β-dystroglycan have 
been reported in a crystal structure : H3076, T3081, Y3072, and W3083 (Huang 
et al., 2000).  β–dystroglycan is a transmembrane protein and a component of 
the complex that binds the extracellular basal lamina (Ervasti and Campbell, 
1991).  The interactions of dystrophin with both actin filaments and microtubules 
and then β–dystroglycan effectively links the cytoskeleton to the extra-cellular 
matrix and localizes dystrophin to the sarcolemma of muscle cells (Zubrzycka-
Gaarn et al., 1988).  
 While full-length dystrophin is an extremely large protein, transcription 
from unique promoter regions result in multiple small isoforms of dystrophin, 
each a different length C-terminal fragment (Blake et al., 2002).  After full-length 
dystrophin (Dp427), the largest isoform is Dp260 (named for its molecular 
weight) which is expressed in the retina (D’Souza et al., 1995).  While it has a 
unique N-terminus, it is identical from SLR 10 to the C-terminus of full-length 
dystrophin and so mimics full-length dystrophin in all of its C-terminal functions 
such as binding to β–dystroglycan.  Dp140 is expressed in the central nervous 
system and in the kidney (Lidov et al., 1995), and Dp116 in the peripheral nerves 
(Byers et al., 1993).  Another notable isoform, Dp71, has been shown to be 
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expressed in neurons and contains no spectrin-like repeats, but only the CR and 
CT domains (Lederfein et al., 1992).  While many isoforms of dystrophin have 
been identified in cells other than muscle, the functions of these proteins are not 
well studied.  It is interesting to note, however, that mutations within these most 
C-terminal domains would affect each of the dystrophin isoforms. 
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Duchenne Muscular Dystrophy 
 Since DMD is the largest gene in the genome, it is statistically more prone 
to de novo mutation; and because it is encoded on the X-chromosome, males 
only have one chance for a functional copy.  Therefore the incidence of 
dystrophinopathies is approximately 1 in 4000 live male births (Mendell et al., 
2012), making it the most common muscular dystrophy.  Males who unfortunately 
harbor a disease-causing mutation in their single copy of the DMD gene develop 
a muscular dystrophy either with severe symptoms referred to as Duchenne 
(DMD) (OMIM: 310200) or milder symptoms referred to as Becker (BMD) (OMIM: 
300376) (Hoffman et al., 1987a).  Generally, patients with milder symptoms have 
in-frame deletions resulting in an internally-truncated dystrophin protein (Monaco 
et al., 1988), while more severely-affected patients have out-of-frame deletions or 
nonsense mutations resulting in a lack of dystrophin expression (Koenig et al., 
1989).  
 The clinical symptoms of DMD were first described in the 1830-1860’s by 
a few physicians, but the one that became associated with the disease was 
Duchenne (Duchenne, 1861).  Symptoms onset at approximately 5 years of age 
and include elevated serum creatine kinase, muscle weakness, decreased ability 
to perform physical activities, calf muscle hypertrophy, and often mild cognitive 
impairment.  One of the earliest clinical signs described was the Gower’s 
maneuver which is a common mechanism the boys use to raise themselves up to 
standing that is necessary because of their weak leg muscles (Figure 1.3)  
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(Gowers, 1886).  Muscle degeneration is progressive and boys are often wheel 
chair bound in their teenage years.  Fatality occurs in the second or third decade 
of life, often due to cardiomyopathy or respiratory failure (Rall and Grimm, 2012).  
Support of a ventilator extends life expectancy by a few years, and 
corticosteroids have been shown to alleviate some symptoms through poorly 
understood mechanisms (Angelini, 2007). 
 The causative mutations for patients with Duchenne/Becker muscular 
dystrophy span the entire spectrum of possible mutations.  In 2006 it was 
calculated that 72% of reported cases were caused by intragenic deletions 
(Aartsma-Rus et al., 2006).  The majority of these deletions occur in exons 45-
53, making this region a “hot spot”.  Duplications were found to occur in 7% of 
patients, including single- and multi-exon duplications; the most common one 
reported is a single duplication of exon 2 (White et al., 2006).  Up to 30% of 
reported cases are caused by single point mutations.  The majority of these are 
nonsense mutations, leading to a premature stop-codon and the severe 
symptoms of Duchenne muscular dystrophy.  The remaining mutations are 
missense mutations, causing a single amino acid change in the protein and a 
wide spectrum of symptoms ranging from Duchenne to Becker diagnoses.  While 
missense mutations are rare, they offer insight into the structure and function of 
dystrophin, and they have the potential for alternate therapeutic interventions.   
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Amino Acid Substitutions in Dystrophin 
 The full-length muscle isoform of human dystrophin is comprised of 3685 
amino acids, and there are several incidences of substitutions that differ from the 
reference sequence.  The Leiden Muscular Dystrophy Pages (www.dmd.nl) 
(Aartsma-Rus et al., 2006) is a database of all dystrophin mutations found in 
DMD/BMD patients.  We compared all of the reported unique missense 
mutations to all amino acid substitutions found in the general population recorded 
in the Single Nucleotide Polymorphism (SNP) database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/).  The distribution of these unique 
amino acid changes across the primary sequence of dystrophin is different 
depending on whether the substitutions associate with disease or are present in 
the population (Figure 1.4).  The distribution of missense mutations (shown in 
red) has noticeable peaks in the NT and CT domains, while there are no obvious 
hotspots for missense mutations in the large SLR domain.  In comparison, SNP 
substitutions (shown in green) appear with higher frequency throughout the SLR 
domain.  When analyzed as a function of dystrophin structural domain, there was 
a significant difference in the proportion of substitutions that cause disease 
between the NT and SLR (z-score=7.02, p<0.0001) and between the CT and 
SLR (z-score=4.97, p<0.0001).  There was no difference between proportions in 
the NT and CT.  These data suggest that if an amino acid change occurs in the 
NT or CT it is more likely to cause disease than if it had occurred in the SLR 
domain.   
  11 
 This thesis will largely focus on two missense mutations that were 
discovered in patients with Duchenne/Becker muscular dystrophy, L54R and 
L172H; and one amino acid substitution that is found in a small percentage of the 
population and is not associated with disease, I232M.  All three amino acid 
changes are located within the N-terminal ABD1, for a more equivalent 
comparison between the molecular effects of each.   
 The first missense mutation discovered in dystrophin was L54R (Prior et 
al., 1993).  Previous to this study, patients presenting with muscular dystrophy 
symptoms were screened by multiplex PCR, the clinical standard at the time.  
This technique, however, is only able to detect large deletions or insertions and a 
set of 105 DMD patients remained with undefined mutations.  Through the use of 
heteroduplex PCR (White et al., 1992) they were able to detect a single T to G 
transversion in exon 3 of one patient resulting in a leucine to arginine amino acid 
change in dystrophin.  It was hypothesized that this was a severely deleterious 
substitution given that this leucine is conserved in mouse and chicken dystrophin, 
and that it changes a non-polar, hydrophobic amino acid into a basic, positively 
charged one.  Indeed the patient was only 8 years old at the time of molecular 
diagnosis and presented with severe muscle weakness and exhibited the 
Gower’s maneuver.  Western blot analysis from muscle biopsy showed a large 
decrease in full-length dystrophin protein compared to an unaffected control.  
Immunofluorescent staining of muscle sections showed dystrophin properly 
localized to the sarcolemma, but at reduced intensity.  Missense mutation L54R 
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clearly represents a substitution that causes the severe symptoms of Duchenne 
muscular dystrophy.   
 With the advancement of sequencing technology, a group was able to 
amplify dystrophin cDNA from a set of 18 muscular dystrophy patients with 
unknown genetic causes and then sequence each sample and align it to the 
reference sequence (Hamed et al., 2005).  Several novel mutations were 
discovered including a T to A nucleotide change in exon 6 causing the L172H 
substitution.  This leucine is also conserved across mouse, dog, and chicken; 
and histidine is, similarly to L54R, a change to a basic, positively-charged amino 
acid.  The L172H mutation, however, was found in a mildly-affected patient who 
presented with symptoms at 42 years of age.  Muscle biopsy revealed decreased 
levels of full-length dystrophin by western blot and correct localization by 
immunofluorescent staining.  L172H serves as a good representative of 
missense mutations that cause the mild symptoms of Becker muscular 
dystrophy.  Together, L54R and L172H, can potentially help us to distinguish 
between the molecular mechanisms of substitutions that cause severe symptoms 
and those that cause mild.    
 In addition to missense mutations that cause disease, there are several 
benign amino acid changes expressed by small portions of the population within 
the N-terminal ABD1 of dystrophin.  After the completion of the human genome 
reference sequence in 2003, several efforts were started to find the variants that 
existed in the population, including the International HapMap Consortium and the 
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1000 Genomes Project (Pennisi, 2010; Buchanan et al., 2012).  Between these 
two major projects over 10 million single nucleotide polymorphism (SNPs) have 
been discovered.  From the deposited data in the SNP database 
(ncbi.nlm.nih.gov/snp), the protein coding region of dystrophin contains over 450 
nucleotide variants, approximately half of which are non-synonymous.  One of 
these is amino acid substitution I232M, validated by multiple, independent 
submissions to the database (rs145668843).  It is not unreasonable that this 
substitution does not cause disease given that both isoleucine and methionine 
are hydrophobic, non-polar amino acids.  In this thesis I232M serves as an amino 
acid substitution control in addition to the “WT” reference sequence control for 
dystrophin. 
 Previous work from our lab analyzed the biochemical and biophysical 
consequences of several missense mutations found in the N-terminal ABD1, 
including L54R and L172H (Henderson et al., 2010).  It was hypothesized that 
mutations in this domain could decrease the actin-binding affinity of dystrophin, 
so mutations were engineered into full-length mouse dystrophin cDNA and 
protein purified from a baculovirus expression system.  Cosedimentation assays 
with filamentous actin revealed that mutations K18N and L54R significantly 
decreased the binding affinity, but only by 4-fold from a Kd of 0.223µM to Kd’s of 
0.76µM and 0.85µM respectively.  The four other missense mutations (including 
L172H) had no effect on actin affinity.  Biophysical analysis of the full-length 
proteins, however, revealed that each of the mutations rendered dystrophin more 
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insoluble, more likely to self-pellet by ultracentrifugation, and less stable during 
thermal denaturation.  Protein instability is a likely mechanism of disease in 
dystrophin missense patients, but the cellular and physiological consequences of 
these mutations has not yet been examined. 
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Current Therapies for Duchenne Muscular Dystrophy 
Gene therapy 
 Gene replacement of dystrophin has been a difficult task given that the 
cDNA is approximately 14kb.  Therefore studies have focused on creating 
functional mini- and micro- versions of dystrophin which are small enough to be 
delivered systemically by adeno-associated virus (AAV) (Watchko et al., 2002; 
Gregorevic et al., 2004).  Administration of these viral vectors in mdx mice leads 
to micro-dystrophin expression and reduced CK activity.  Progression of this 
therapy into human patients has been complicated by possible immune 
responses to the foreign dystrophin protein.  A study administering mini-
dystrophin in rAAV found that there was a CD4+ T cell response to the 
transgene, decreasing the efficacy of this treatment (Mendell et al., 2010).  
Future studies aim to develop better vectors and more specific promoters in 
order to decrease immune response.   
Protein therapy 
 Due to the immune response seen in gene replacement therapies, several 
studies have examined the possibility using the homolog of dystrophin, utrophin 
as a protein replacement therapy.  Utrophin is structurally similar to dystrophin 
and is found at the sarcolemma during fetal development but in adult muscle is 
restricted to the myotendinous and neuromuscular junctions.  It has been shown 
that utrophin can functionally replace dystrophin in mdx mice (Miura and Jasmin, 
2006).  Increasing utrophin levels can be achieved by either up-regulating 
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endogenous transcription and translation (Chakkalakal et al., 2008; Moorwood et 
al., 2013) or delivering exogenous utrophin protein (Sonnemann et al., 2009).  
Such therapies would avoid an immune response since utrophin is normally 
expressed in fetal muscle and in adult muscle junctions.  There is, however, 
increasing evidence that utrophin does not replace all of the functions of 
dystrophin including nNOS and microtubule binding (Li et al., 2010a; Belanto et 
al., 2014). 
Exon skipping 
 One of the emerging therapies targeting the endogenous DMD transcript 
is exon-skipping.  In this method oligonucleotides with a morpholino backbone 
are synthesized with antisense sequence to a region of dystrophin pre-mRNA 
(Alter et al., 2006).  The antisense oligonucleotide (AON) binds to the nascent 
transcript causing the splicing machinery to skip over the targeted exon.  This 
therapy is most applicable to patients with out-of-frame deletions or duplications, 
where exon-skipping leads to restoration of the reading frame.  Clinical trials of 
an AON targeted to exon 51 have demonstrated restored dystrophin protein and 
improved physiological activity (Goemans et al., 2011).  Exon-skipping obviously 
leads to small deletions in the protein product and therefore research is ongoing 
to determine the best non-native junctions possible.   
Nonsense read-through 
 Many DMD patients harbor a nonsense mutation, as discussed above.  It 
was discovered that the antibiotic gentamicin binds to 18S rRNA causing 
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ribosomes to sometimes “read-through” a stop codon, inserting a random amino 
acid instead (Palmer et al., 1979).  In vitro and in vivo administration of 
gentamicin to the nonsense mutation mouse model (mdx) lead to dystrophin 
expression and proper localization (Barton-Davis et al., 1999).  Subsequent 
studies have brought gentamicin to the clinic with mixed results (Malik et al., 
2010).  The next generation read-through drug, Ataluren, is not an antibiotic and 
has been shown to effectively read-through all three stop codons at low dosages 
(Peltz et al., 2013).  Ataluren has shown positive results in nonsense models of 
cystic fibrosis, dysferlin-deficient myopathy, Hurler syndrome, and Duchenne 
muscular dystrophy in the mdx mouse; this drug is currently in phase 3 clinical 
trials for boys with DMD due to nonsense mutations 
(clinicaltrials.gov/show/NCT01826487).  This is one of the first examples of 
personalized medicine that is not targeting a disease but rather a specific 
molecular cause.  It is interesting to note that this treatment leads to a phenotypic 
missense mutation. As of yet there are no personalized medicine approaches 
that are being explored for DMD patients with missense mutations.  
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Questions Addressed by this Thesis 
 Previous work in our lab has demonstrated that missense mutations in the 
N-terminal ABD1 domain cause protein instability in vitro (Henderson et al., 
2010).  And other groups have studied the in vitro effects of missense mutations 
in other domains of dystrophin, but in small fragment peptides (Legardinier et al. 
2009; Acsadi et al. 2012).  Given that WT full-length dystrophin is stable and 
unfolds in one cooperative transition and that some isolated fragments of WT 
dystrophin are not even stable enough to be studied in vitro, we aimed to study 
missense mutations in all the major domains in a full-length construct to answer 
the question: Do missense mutations in every domain of dystrophin have 
the same propensity to cause protein instability in vitro? 
 The biophysical characterization of mutations L54R and L172H showed 
that each caused protein instability.  Protein instability can have several different 
consequences when expressed in the cellular environment including protein 
aggregation, protein mislocalization, or protein degradation (Liu et al., 2009; Lee 
et al., 2011).  It is currently unknown what happens to full-length mutant 
dystrophin protein in a cell.  Therefore we generated a cell culture model in order 
to potentially distinguish between the severe symptoms associated with L54R 
and the mild symptoms with L172H, to serve as a screening platform for small 
molecular therapeutics, and most importantly to answer the question:  What are 
the cellular consequences for the dystrophin protein when harboring 
missense mutations L54R and L172H? 
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 Dystrophin is a structural protein and therefore its full activity cannot be 
measured in a cell culture model, but rather only in vivo through physiological 
assays.  We wanted to see if the molecular phenotypes of the cell culture model 
would translate to an animal model, so we generated two transgenic mouse 
lines.  These lines will also demonstrate the tissue and whole body 
consequences of the missense mutations, serve as models for new potential 
therapeutics, and answer the question: Can transgenic mice harboring 
missense mutations L54R and L172H faithfully recapitulate the severe and 
mild phenotypes of the patients which they are modeling? 
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Figures 
 
 
 
 
 
Figure 1.1:  Dystrophin Glycoprotein Complex (DGC).  The core DGC 
components are shown in red: dystrophin, α- and β-dystroglycan, syntrophin, 
dystrobrevin, the sarcoglycans and sarcospan.  Shown in blue and white are 
other structural components of the costamere, those in blue are found 
upregulated in dystrophin deficient muscle.  Figure from Ervasti 2007. 
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Figure 1.2: Schematic representation of dystrophin protein domains.  ABD1 
= actin binding domain 1, ABD2 = actin binding domain 2, H1-4 = hinges, DgBD 
= dystroglycan binding domain.  Below are the 3 crystal structures that have 
been generated for dystrophin.  Crystal structure of the ABD1 = 1DXX (Norwood 
et al., 2000).  Crystal structure of one of the spectrin repeats = 3UUL (Muthu et 
al., 2012).  Crystal structure of the CR DgBD = 1EG4 (Huang et al., 2000). 
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Figure 1.3: Gower’s Maneuver.  Technique young boys with Duchenne 
muscular dystrophy use to raise themselves to standing, first described by 
(Gowers, 1886).  Image illustrated by Alison Burke (Punnoose et al., 2011). 
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Figure 1.4: Distribution of dystrophin missense mutations  (A) Total 
documented amino acid substitutions are shown as they are distributed along the 
primary sequence of dystrophin.  The top graph in red represents all unique 
missense mutations found in patients with DMD/BMD (Leiden pages).  The 
bottom graph in green represents unique, non-synonymous SNPs found in the 
population (dbSNP).  NT: Amino Terminus (a.a. 1-252), SLR: Spectrin Like 
Repeats (also known as central rod region) (a.a. 253-3112), CT: Carboxy 
Terminus (a.a. 3113-3685).   
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Chapter 2 
 
 
 A Biophysical Model of Missense  
Mutations in Dystrophin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial sub-cloning of full-length mouse dystrophin into Gateway vectors was 
performed collaboratively with Joseph Belanto. All subsequent cloning, protein 
purification, and biophysical analyses were performed by Dana Talsness.  
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Summary 
 Duchenne and Becker Muscular Dystrophies (DBMD) are debilitating 
disorders affecting males with a mutation in their single copy of the dystrophin 
gene, and a growing number of DBMD cases have been linked to missense 
mutations.  While many of these missense mutations are localized in the amino 
terminal (NT) actin-binding domain (ABD1), previous studies have shown these 
to affect protein thermal stability rather than cause a substantive loss in actin 
binding activity. To determine whether missense mutations in other dystrophin 
domains also cause protein instability, we characterized an array of disease-
associated amino acid substitutions by in vitro expression in recombinant Dp260, 
or full-length dystrophin (Dp427).  Biochemical analyses of mutations within the 
spectrin like repeats (SLR) of the central rod domain showed no perturbations in 
solubility or stability.  Mutations in the carboxy terminal (CT) domain, however, 
partitioned into two groups: those without effect and those that significantly 
impaired protein solubility and expression levels.  Spectroscopic analyses of the 
soluble dystrophin fraction revealed that the stability of the secondary structure 
could be affected by mutations in both the NT and CT domains, while the stability 
of the tertiary structure was affected only by mutations in the NT.  These findings 
suggest that disease-causing missense mutations differentially affect the stability 
and solubility of dystrophin dependent on the domain in which they reside. 
  
  26 
Introduction 
 The majority of missense mutations that have been studied at the protein 
level using biophysical methods are located in the amino terminal (NT) actin-
binding domain 1 (ABD1) (Henderson et al., 2010; Singh et al., 2010). While 
none of the ABD1 mutations studied were found to dramatically reduce the actin-
binding activity of dystrophin in vitro, all caused protein instability as evidenced 
by decreased solubility and non-cooperative melting transitions (Henderson et 
al., 2010), and also plaque-like aggregation when expressed in NT-fragment 
peptides (Singh et al., 2010).  Consistent with these findings, a recent clinical 
study reported a DMD patient encoding L53R in the NT who had reduced 
sarcolemmal dystrophin immunoreactivity in the muscle biopsy (Juan-Mateu et 
al., 2013), likely due to a decrease in protein stability similar to the previously 
biophysically characterized mutations in the NT domain. 
 Clinical studies have also identified DBMD patients with amino acid 
substitutions within the 24 spectrin-like repeats (SLR) of the central rod domain 
that result in mild to severe disease.  Two mildly affected siblings encoding 
L427P in SLR1 were recently reported, and subsequent biochemical analyses of 
the mutant SLR1 peptide demonstrated misfolding in vitro (Acsadi et al., 2012).  
Other patients have been found with two proximate missense mutations (Juan-
Mateu et al., 2013; Legardinier et al., 2009), and one study concluded that both 
mutations were necessary to cause protein instability in the SLR peptide 
(Legardinier et al., 2009).  It remains unclear whether mutations in the SLR 
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domain are likely to cause instability or not.  This lack of understanding is 
partially due to previous studies expressing mutations in peptide fragments, and 
behaviors of even WT SLRs have been shown to vary dramatically when studied 
in isolation (Mirza et al., 2010).  While these studies suggest the molecular 
consequences of individual missense mutations, comparing mutations within the 
SLR requires expression in the context of full-length dystrophin isoforms.   
 DBMD patients with missense mutations in the carboxy-terminal (CT) 
domain often display severe symptoms including a DMD patient encoding 
C3340Y (Lenk et al., 1996), and another encoding D3335H (Goldberg et al., 
1998). The CT domain of dystrophin consists of a cysteine-rich region that binds 
beta-dystroglycan (Suzuki et al., 1994), and an unstructured “tail” region that 
binds to syntrophins (Ahn and Kunkel, 1995). Previous studies of CT missense 
mutations have been limited to assessing their effects on beta-dystroglycan 
binding in vitro or localization in heterologous cells, both using isolated 
recombinant domains (Ishikawa-Sakurai et al., 2004; Draviam et al., 2006). A 
recent report revealed the first missense mutation to definitively lack beta-
dystroglycan binding in vivo (Vulin et al., 2014). Yet, other missense mutations 
do not appear to ablate dystroglycan binding, and it is not known how they affect 
the biophysical stability of full-length dystrophin protein. 
 To better understand the biophysical consequences of amino acid 
substitutions distributed throughout the three principal domains of dystrophin 
(NT, SLR, CT), we generated a biophysical model of an array of disease-
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associated missense mutations and non-disease nsSNP in full-length purified 
dystrophin.  Of the five disease-associated substitutions and three nsSNPs 
analyzed in the SLR of the central rod region, none appeared to markedly 
decrease protein solubility or stability.  Analysis of six disease-associated 
substitutions and one nsSNP within the CT domain also revealed some 
mutations without effect on protein stability or solubility.  Yet other CT mutations 
showed significantly decreased solubility and expression level.  Biophysical 
analyses of mutants in full-length dystrophin (Dp427) revealed that while both NT 
and CT mutations can decrease solubility and expression, only NT mutations 
drastically alter the tertiary folding and stability of soluble protein.  Our results 
demonstrate that domain location influences the biophysical consequences of 
disease-causing missense mutations in dystrophin in vitro. 
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Materials and Methods 
In silico Amino Acid Substitution Analysis 
Supplemental Table 1 summarizes all data obtained for in silico analysis.  The list 
of non-synonymous SNPs for the human DMD gene was obtained from the SNP 
database on the National Center for Bioinformatics webpage 
(http://www.ncbi.nlm.nih.gov/snp).  The list of disease-associated missense 
mutations were obtained from the Leiden Muscular Dystrophy pages 
(http://www.dmd.nl/), and any that overlapped with known SNPs were considered 
not associated with disease and were discarded.  Unique amino acid 
substitutions were plotted as a distribution across the primary amino acid 
sequence.  Statistical analysis of the proportion of amino acid substitutions (n) 
that cause disease (x) for the three domains NT: Amino Terminus (a.a. 1-252), 
SLR: Spectrin Like Repeats (also known as central rod region) (a.a. 253-3112), 
CT: Carboxy Terminus (a.a. 3113-3685) were calculated.  NT: n=36, x=26, 
p=0.7222.  SLR: n=230, x=41, p=0.1782.  CT: n=44, x=23, p=0.5227.  H0: p1=p2.  
z-score comparisons between the three proportions were calculated and 
significance determined at a level of α=0.05.   
Cloning 
The Dp260 and Dp427 mouse dystrophin cDNA constructs (NM_007868.5) were 
cloned into the entry vector pENTR™/D-TOPO® (Life Technologies) according to 
manufacturer’s instructions.  Individual nucleotide changes corresponding to 
human amino acid changes were made with the following site directed 
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mutagenesis reaction: 39.5µl dH2O, 5µl Pfu buffer, 200µM dNTPs, 125ng of Fwd 
mutation primer, 125ng Rev mutation primer, 1µl template plasmid, 1µl PfuUltra II 
Fusion HotStart polymerase (Agilent).  Reaction was cycled with the protocol: 92° 
for 2 min, 35 cycles of [92° for 1 min, 50° for 1 min, 68° for 10 min], 68° for 15 
min.  Nucleotide changes were verified by Sanger sequencing.  
Protein expression and purification 
Construct cassettes were recombined from entry vector into the Baculovirus 
destination vector pDEST™8 using Life Technology’s Gateway® LR Clonase® 
(Hartley, 2000). These plasmids were transformed into DH10Bac competent 
E.coli, so that the expression insert could transpose into the Bacmid DNA.  
Bacmid DNA was purified according to manufacturer’s protocol and transfected 
into Sf9 insect cells with the transfection reagent Cellfectin® II (Life 
Technologies).  All culturing of insect cells was performed in the serum-free 
media Sf-900™ II SFM (Life Technologies) at a concentration of 1×106 cells/mL.  
A maximum titer of virus was produced by successive infections.  The P2 
baculovirus stocks were used in excess volumes to infect 250mL cultures for 72-
hour expressions of recombinant protein such that variable multiplicities of 
infection (MOI) were negligible.  After the 72 hours of protein expression, insect 
cells were pelleted and re-suspended in a solution of Phosphate Buffered Saline 
(PBS) [8mM NaH2PO4, 42mM Na2HPO4, 150mM NaCl] and protease inhibitors 
[100nM Aprotonin, 10mg/ml E-64, 100µM Leupeptin, 1mM PMSF, 1µg/ml 
Pepstatin], and then lysed by sonication for 30 seconds 3 times at 30% power.  
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The lysate was applied to an anti-FLAG M2 agarose column (Sigma Aldrich) and 
washed with >10 volumes of PBS + protease inhibitor solution. Bound protein 
was eluted with buffer containing 100µg/ml FLAG peptide.  The purified protein 
was dialyzed overnight in 2L of PBS and concentrated using an Amicon 
Centrifugal Filter unit (UFC801024).  Purity was assessed by Coomassie staining 
of an SDS-PAGE separation and concentration determined by A280. 
Solubility Quantification 
Sf9 insect cells were infected with high titer Baculovirus encoding the protein of 
interest and incubated for 48 hours (Dp260) or 72 hours (Dp427).  Cells were 
then collected and lysed in a solution of PBS (with protease inhibitors as above) 
+ 1% Triton X-100 for 30 minutes.  Samples were centrifuged at >20,000 x g for 
10 minutes.  Supernatant was collected as the soluble fraction and the insoluble 
pellet resuspended in the same volume of a solution of 2M Urea, 1% SDS and 
incubated at 50°C for 30 minutes.  All samples were boiled at 95° for 5 minutes 
and equal volumes loaded onto a 3-12% polyacrylamide gel.  Samples were 
electrophoresed at 150V for 1 hour, then transferred to PVDF membrane at 
100V/0.7Amp for 1 hour.  Membranes were blocked in 5% non-fat milk in 
phosphate buffered saline 0.1% Tween solution for 1 hour.  FLAG-Dystrophin 
fusion protein was detected by M2 α-FLAG primary antibody (Sigma) at 1:1000 in 
blocking buffer, then secondary antibody anti-mouse IgG Dylight® 800 (Cell 
Signaling) at 1:10,000 in blocking buffer.  Secondary antibody signal was 
visualized on Licor’s Odyssey® Infrared Imaging System and band density 
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calculated with Odyssey Software v2.1.   
Circular Dichroism (CD) 
Purified protein was prepared at a concentration of 0.5mg/ml for Dp260 and 
0.3mg/ml for Dp427 in PBS.  Samples were centrifuged at >20,000 x g for 10 
minutes to pellet dust.  Absorption spectra were acquired with a Jasco J-815 
spectropolarimeter, at 20°C as controlled by a Peltier device, from 200 to 260nm 
wavelength.  Spectra were then acquired at 1° intervals from 20-90° and the 
characteristic alpha-helical wavelength (θ222) recorded.  Values of ellipticity were 
normalized from 0 to 1 for each sample and plotted against temperature, then fit 
by regression analysis in Sigma Plot (Systat Software, Inc.) using an equation for 
a two state or three state unfolding model.(Legardinier et al., 2009) 
Differential Scanning Fluorimetry (DSF) 
Method described by Niesen et al.(Niesen et al., 2007)  Purified protein at a 
concentration of 0.5mg/ml for Dp260 and 0.3mg/ml for Dp427 in PBS was 
incubated with the fluorescent dye SYPRO® Orange (Life Technologies™ 
#S6650) at a concentration of 1:1000.  When bound to hydrophobic regions of 
protein, the dye fluoresces with an emission of 610nm wavelength.  Emission 
was measured with a BioRad iQ light cycler as temperature was increased from 
20° to 90°.  Relative Fluorescent Units were measured and standardized to show 
a 0.0 to 1.0 fraction of unfolded protein and plotted against temperature.  Curves 
were fit by regression analysis in Sigma Plot (Systat Software, Inc.) using an 
equation for a two state unfolding model.(Legardinier et al., 2009)  Samples were 
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measured in technical triplicate.   
Dynamic Light Scattering (DLS) 
Purified protein was diluted to a concentration of 0.1mg/ml for Dp260 or 
0.05mg/mL for Dp427 in PBS.  Samples were centrifuged at >20,000 x g for 10 
minutes to pellet dust.  Light scattering was measured by the Malvern Instrument 
Zetasizer µV for 100uL of sample in a disposable cuvette.  Scattering intensity 
was measured 13 times over 10-second intervals, and each interval correlated as 
a function of time.  From the correlogram, a diffusion coefficient was extracted 
and used to calculate particle size with the Stokes-Einstein equation.  Malvern 
Zetasizer software reports the hydrodynamic radius of the particle as a Z-
average in nm and the polydispersity Index (PdI) of the solution on a scale or 0 to 
1 where 0 is perfectly uniform in size.  
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Results 
Biophysical characterization of missense mutations in the CT and SLR domains 
of Dp260 
 Several DBMD and SNP amino acid changes in the SLR and CT domains 
were selected for biophysical characterization in recombinant Dp260 protein, 
which offers the context of an endogenous protein yet is logistically easier than 
full-length dystrophin (Table 2.1).  Proteins were engineered in a baculovirus 
system and expressed in Sf9 insect cells with an amino-terminal FLAG epitope 
(Figure 2.1).  To determine the solubility of each, cells were fractionated into 
soluble (S) and insoluble (I) portions (Figure 2.2A) and the percentage of soluble 
protein was quantified (Figure 2.2B).  The WT Dp260 itself was only ~50% 
soluble, most likely due to overexpression in the baculovirus system, yet provides 
a standard against which to measure the substituted proteins.  None of the amino 
acid changes in the SLR domain caused a decrease in solubility of the protein 
relative to WT Dp260.  In the CT domain however, D3335Y caused a significant 
reduction in the percent soluble protein (p<0.01), and A3311P, C3313F, and 
C3340Y caused an even more dramatic decrease (p<0.0005).  Total protein 
expression levels (S + I) normalized to WT (Figure 2.2C) confirmed a highly 
significant reduction of C3207R expression (p<0.01) that was apparent from the 
raw data (Figure 2.2A). 
 Each of the substituted proteins were then expressed on a larger scale in 
the insect cells and purified by FLAG-affinity chromatography.  Total purified 
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protein is shown with equal loading (by A280) for SDS-PAGE separation and 
Coomassie staining (Figure 2.2D).  Purification results confirm solubility and total 
protein quantifications; C3313F is visibly reduced in the purification sample and 
C3207R and C3340Y are not observable at all by Coomassie stain.  These 
results indicate that several of the amino acid substitutions in the CT domain of 
Dp260 decrease the solubility and purifiable fraction.  While not all proteins are 
visible by Coomassie, subsequent analyses indicate that each is present in the 
respective purification samples. 
 Because many of the SLR and CT mutations were comparable to WT 
Dp260 in terms of solubility and expression, we investigated whether any of the 
purified proteins exhibited altered secondary structure as analyzed by circular 
dichroism (CD) spectroscopy.  Absorption spectra (Figure 2.3A) for each protein 
were characteristic of a highly alpha-helical peptide with minima at 208 and 
222nm.  The magnitude of absorption is visibly reduced for C3207R and 
C3340Y, indicative of the lower percentage content in the purification sample as 
was seen in Figure 2.2.  Yet each of these cysteine mutants maintains the alpha-
helical secondary structure.  As a negative control, uninfected Sf9 lysate was 
purified in a similar manner and the elution measured by CD; no absorption 
spectrum was observed (data not shown).  To determine the thermal stability of 
the secondary structure, the 222nm minimum was monitored over a temperature 
course (Figure 2.3B).  The WT Dp260 protein was observed to exhibit two 
unfolding transitions (Tm’s = 52.7°C, 74.8°C), consistent with previous reports 
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(Henderson et al., 2011; Mirza et al., 2010).  While some of the substituted SLR 
(P3011S and E3032K) and CT domain proteins (A3311P, C3313F, and R3673K) 
exhibited two-transition unfolding similar to WT, several others exhibited single-
transition unfolding (Figure 2.3B).  Thus, there was no obvious relationship 
between thermal stability and disease association for substitutions in the SLR or 
CT. 
 We also monitored the unfolding of each substituted protein by differential 
scanning fluorimetry (DSF), which measures the tertiary structure of a protein as 
assessed by hydrophobic residue exposure (Niesen et al., 2007).  Monitoring 
DSF signal as a function of temperature revealed a single-transition unfolding for 
WT Dp260 protein with a Tm of 43.31°C (data not shown).  This melting inflection 
point is lower than that calculated for the CD melt, as is expected because 
tertiary structure is lost before secondary structure during thermal denaturation.  
All amino acid substitutions in the SLR and CT (both disease-associated and 
SNP) had a similar transition with similar Tm.  These data indicate that mutations 
in the SLR and CT domains have no effect on the tertiary stability of the Dp260 
protein. 
 Lastly we analyzed the purified Dp260 proteins by Dynamic Light 
Scattering (DLS).  Because DLS calculations of molecular weight depend on the 
assumption of spherical shape, absolute values of hydrodynamic radius (z-
average) were not used to calculate molecular weight of rod-shaped Dp260, but 
rather were used for relative comparisons.  DLS for WT Dp71, Dp260, and 
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Dp427 reported z-average values of 16.76±0.11, 24.76±0.11, and 40.86±1.05nm 
respectively (data not shown).  DLS of all amino acid substituted Dp260 proteins 
reveals some heterogeneity in size, yet all are comparable to WT (Figure 2.4A).  
While WT protein served as a negative control of aggregation, our equivalent 
positive control was WT protein boiled for 5 minutes and then brought back to 
room temperature.  Various concentrations of protein were boiled and each had 
z-averages between 150-200nm (data not shown).  None of the amino acid 
changes caused this magnitude of radius, as would be expected in a plaque-type 
aggregation.  The polydispersity index (PdI) can also be measured by DLS on a 
scale from 0 to 1.  WT Dp260 has a PdI within quality control standards, as do 
each of the substituted proteins (Figure 2.4B) (ISO standards document 13321).  
The amino acid changes C3207R, C3313F, and C3340Y have a visibly increased 
PdI, which we believe is due to these proteins comprising a lower percentage of 
the purified sample as seen in Figure 2.2D, rather than indicating protein 
aggregation.  The size and polydispersity were measured by DLS at several 
different concentrations and for time courses (data not shown); none of the 
substituted proteins were significantly different than WT.  Together these data 
indicated that the soluble Dp260 protein purified from cells is not prone to plaque-
like aggregation.  
Biophysical characterization of missense mutations in the NT, SLR, and CT 
domains of Dp427 
 Results from the Dp260 constructs were obscured by the nature of WT 
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Dp260 (particularly in regards to CD melt transitions), and we wanted to directly 
compare amino acid substitutions in the SLR and CT domains with previously 
characterized substitutions in the NT domain.  Therefore we engineered two 
disease-associated substitutions and one nsSNP for each of the three domains 
into full-length dystrophin, Dp427 (Table 2.1).  Constructs were again expressed 
in insect cells via the baculovirus system.  Cell lysates were fractioned into (S) 
and insoluble (I) portions and Dp427 levels analyzed (Figure 2.5A).  
Quantification of the percent soluble protein showed no significant decreases in 
any of the amino acid substituted proteins compared to WT, although L54R 
appears to trend towards a decrease (Figure 2.5B).  C3207R appears to be 
highly soluble, but this calculation should not be taken too literally as it is 
obviously the result of dividing by values near zero.  Quantification of the total 
expressed protein relative to WT (Figure 2.5C), revealed a significant decrease 
for L54R (p<0.05); and as expected from the raw data (Figure 2.5A), a highly 
significant decrease for C3207R (p<0.0001).  Expression of protein in insect cells 
was then scaled up for purification, and total purified protein is shown with equal 
loading (by A280) for SDS-PAGE separation and Coomassie staining (Figure 
2.5D).  Dp427 C3207R represented a smaller percentage component of the 
purified sample confirming total expression levels in Figure 2.5C.  Also as 
expected from results in Dp260, none of the substitutions in the SLR domain 
affected protein solubility or purification ability. 
 Purified protein samples were measured by circular dichroism (CD) to 
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determine global secondary structure (Figure 2.6A).  The absorption spectrum of 
Dp427 WT was characteristic of a highly alpha helical protein with minima at 208 
and 222nm and each of the substituted proteins showed similar spectra.  The 
absorption at 222nm was observed over a temperature course to determine 
thermal stability of the secondary structure (Figure 2.6B).  Dp427 WT showed a 
single-step unfolding (Tm = 48.59°).  In the NT domain, L54R displayed a more 
linear unfolding transition indicative of a less stable or heterogeneous folded 
state and consistent with previous reports (Henderson et al., 2010).  Both SNP 
and missense mutations in the SLR domain gave similar melt curves to WT.  In 
the CT domain, C3207R is seen above the WT curve at low temperatures and 
below the WT curve at high temperatures; again this less cooperative transition 
indicates less stability in the secondary structure of this mutant.   
 The differences in CD melt transitions are subtle, so we also examined the 
stability of these full-length Dp427 constructs by Differential Scanning Fluorimetry 
(DSF) which measures the tertiary state of the protein (Figure 2.6C).  Dp427 WT 
gave a melting temperature of 43.36°C.  Both the SNPs and missense mutations 
in the SLR and CT domains gave this same unfolding curve, indicating there 
were no perturbations in the tertiary stability of these proteins.  Yet, large 
differences are noticeable in the NT domain.  Importantly, the SNP I232M shows 
a similar melt curve to WT, while L172H is shifted slightly left (Tm = 42.08°C) 
indicating a decrease in protein stability.  And L54R is far left-shifted (Tm = 
40.03°C) indicating either a large tertiary instability or an already partially 
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unfolded state of the protein at initiation of the experiment.  These data indicate a 
unique disturbance in global folded state caused only by missense mutations 
located in the NT domain of Dp427. 
 To determine the potential aggregation state of the protein we analyzed 
each by Dynamic Light Scattering (DLS).  The z-average relative size of Dp427 
WT was determined to be 40.86±1.05nm and each of the substituted proteins 
gave similar measurements (Figure 2.6D).  None were the orders of magnitude 
larger indicative of amyloid-like aggregations.  The polydispersity of each purified 
protein was similar to WT and within quality control standards (Figure 2.6E).  
Again the dispersity indicates that these amino acid substitutions did not cause 
aggregation in full-length Dp427.  Even the NT mutations that caused global 
misfolding (Figure 2.6C) did not appear to cause aggregation by this highly 
quantitative method. 
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Discussion 
 Here we report on the effect of several disease-causing missense 
mutations found in DBMD patients spanning the three major domains within full-
length dystrophin protein. Firstly, it was observed that all mutations tested in the 
SLR domain had no effect on solubility, stability of secondary or tertiary structure, 
or aggregation state of purified Dp260 or Dp427 protein. Secondly, it was found 
that missense mutations in both the NT and CT can cause subtle effects on the 
solubility and stability of dystrophin. And finally, no missense mutation tested 
caused plaque-like aggregation of the purified protein under the conditions 
tested. It seems that the principle effect of missense mutations in full-length 
protein is insolubility in the cellular context, and that after purification only subtle 
biophysical perturbations are measurable. 
 Several previous biophysical studies of dystrophin missense mutations 
have been performed on isolated recombinant domains (Singh et al., 2010; 
Acsadi et al., 2012; Legardinier et al., 2009; Ishikawa-Sakurai et al., 2004; 
Draviam et al., 2006), but it has been demonstrated that even the WT amino acid 
sequence of some individual SLRs are not stable enough for biophysical 
characterization (Mirza et al., 2010). Therefore, introduction of a missense 
mutation into a stability-compromised peptide fragment may exaggerate the 
effect of the mutation on protein stability. Our data and that of others suggest that 
such context-dependent effects of mutation are evident in naturally occurring 
isoforms of dystrophin. For example, the C3313F mutant version of Dp71 only 
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expressed to a small fraction of the level observed for WT Dp71 and was almost 
completely insoluble when expressed in insect cells, HEK293 cells, or mouse 
skeletal muscle (Vulin et al., 2014), while we observed that increasing amounts 
of this mutant were recovered when expressed in Dp260, or Dp427. The  
C3313F mutant demonstrates that the effects of some missense mutations on 
dystrophin folding and stability are highly context-dependent. 
  Although the effects we observed in Dp260 and Dp427 are subtle, it 
appears that mutations in the two termini of the dystrophin protein are more 
destabilizing than those in the SLRs of the central rod domain. The different 
susceptibilities of the three major domains is likely a result of their inherent 
structures and functions. In the NT, mutations can cause a disturbance in the 
tertiary structure as revealed by DSF. This dependence on domain location may 
be due to the nature of the protein folding process in which chaperones begin to 
fold a nascent peptide as it is translated from amino- to carboxy-terminus 
(Kramer et al., 2009; Zhang and Ignatova, 2011). A mutation that is encountered 
early in the folding process may be more globally destabilizing. In the SLR, none 
of the mutations tested had an effect on solubility and expression of the protein 
or on biophysical stability. The ability of a spectrin repeat to acquire a mutation 
and maintain structure and stability is not unexpected based on the sequence 
variability seen between individual spectrin-like repeats in dystrophin and 
between spectrin repeats in other members of the large family of spectrin-like 
proteins (Pascual et al., 1997; Djinovic-Carugo et al., 2002). In the CT domain, 
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the cysteines which appear to be necessary for proper solubility and expression 
are critical for Zn2+ binding and subsequent structure (Ponting et al., 1996; Hnia 
et al., 2007). The three major domains of dystrophin therefore appear to be 
differentially affected by disease-causing missense mutations. 
 In our system, even the missense mutations associated with severe 
dystrophy in patients (L54R, C3313F) had relatively small biophysical effects in 
vitro so it follows that missense mutations associated with milder dystrophy may 
show no difference from WT protein in vitro. Clearly, such missense mutations 
must affect some aspect of dystrophin structure or function. For instance, they 
may alter the activity of dystrophin for one of its binding-partners as seen for loss 
of beta-dystroglycan binding by Dp71 mutant D3335H (Vulin et al., 2014), as well 
as syntrophin (Ahn and Kunkel, 1995), dystrobrevin (Sadoulet-Puccio et al., 
1997), nNOS (Brenman et al., 1995), phospholipids (DeWolf et al., 1997; 
Legardinier et al., 2008), intermediate filaments (Stone et al., 2005; Bhosle et al., 
2006), or microtubules (Prins et al., 2009). Another possibility is that nucleotide 
changes predicted to effect amino acid substitutions may actually perturb 
transcript splicing (Xing and Lee, 2006; López-Bigas et al., 2005). The 79 exons 
of the dystrophin gene raise the probability that nucleotide substitution may affect 
splicing, which would not be observable in our experimental design. Finally, the 
possibility remains that some of the amino acid changes found in DBMD patients 
are not the causative mutation. The abundance of documented polymorphisms in 
dbSNP demonstrates that a variety of substitutions can occur and not cause 
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disease. 
 In order to move towards a more personalized medicine approach where 
the most effective therapy can be developed for DBMD patients with missense 
mutations, it will be necessary to fully understand how each missense mutation 
affects dystrophin structure and function. Our results reinforce the importance of 
evaluating missense mutations in the context of full-length dystrophin, and likely 
in the context of a mammalian cellular system or model organism. 
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domain a.a. Δ designation reference 
N-terminal 
Domain (NT) 
L54R DMD Prior et al.(Prior et al., 1993) 
L172H BMD Hamed et al.(Hamed et al., 2005) 
I232M SNP rs145668843 
Spectrin-Like 
Repeats, 
(SLR) 
A1872V DMD LMDP 00001 
R2155W SNP rs1800273 
L2267F DMD LMDP 00017 
A2682S DMD LMDP 00001 
D2740G BMD 
Flanigan, et 
al.(Flanigan et al., 
2009) 
Q2937R SNP rs1800280 
P3011S DMD LMDP 00003 
E3032K SNP rs72466562 
C-terminal 
Domain (CT) 
D3187G DMD Taylor et al.(Taylor et al., 2007) 
C3207R DMD Taylor et al.(Taylor et al., 2007) 
A3311P BMD LMDP 00198 
C3313F DMD Flanigan et al.(Flanigan et al., 2003) 
D3335Y DMD/BMD Flanigan et al.(Flanigan et al., 2009) 
C3340Y DMD Lenk et al.(Lenk et al., 1996) 
R3673K SNP rs1795743 
 
Table 2.1:  Selected amino acid substitutions for analysis in Dp260 and full-
length Dp427. Designation of amino acid change is listed by disease on the 
Leiden Muscular Dystrophy Pages (DMD=Duchenne Muscular Dystrophy, 
BMD=Becker Muscular Dystrophy) or as a SNP on dbSNP (NCBI).  SNPs are 
referenced by their rs ID number (marked in green), and disease-associated 
changes by their original publication or Leiden Muscular Dystrophy Pages 
(LMDP) database submitter ID (red).   
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Figures 
 
 
 
 
 
Figure 2.1: Expression construct and experimental concept 
Full-length, mouse dystrophin DNA was subcloned with an N-terminal FLAG 
epitope tag under a polyhedron promoter (pPOLh).  This cassette was 
recombined into the baculovirus genome, or Bacmid DNA.  Bacmid DNA was 
transfected into Sf9 insect cells by lipid-mediated methods.  Virus was expressed 
from the Bacmid DNA while dystrophin protein was expressed from the 
polyhedron promoter; serial infections were performed to maximize viral titer. The 
final viral titer was used to infect a large culture of insect cells which was then 
lysed and dystrophin protein purified by FLAG affinity chromatography. 
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Figure 2.2:  Solubility and expression levels of missense mutations in 
Dp260  (A) Representative immunoblot analysis of soluble fraction (S) and 
insoluble fraction (I) from Sf9 cell lysates infected with baculovirus expressing the 
Dp260 isoform of dystrophin with indicated amino acid change.  (B) 
Quantification of percent solubility by calculating soluble band values divided by 
soluble and insoluble band totals from immunoblots depicted in (A).  n=3.  Red = 
disease associated, green = SNP, significantly decreased from WT (‡ p<0.01), (* 
p<0.0005).  (C) Quantification of the total protein expressed in soluble and 
insoluble band values normalized to WT total on each blot.  n=3.  Significantly 
decreased (‡ p<0.05) (* p<0.01)  (D) Coomassie-stained acrylamide gel of total 
purified protein.  Purified protein was concentrated and then measured by A280.  
10µg of each sample was loaded.  
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Figure 2.3:  Secondary structure and stability of missense mutations in 
Dp260  (A) Circular Dichroism absorption spectra of each Dp260 purified protein.  
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All spectra display molar ellipticity minima at 208 and 222nm indicative of a 
highly alpha-helical protein.  (B) Circular Dichroism melt curves obtained by 
monitoring absorption values at 222nm over temperature gradient of 20-90°.  
Values are normalized from 0-1 fraction unfolded.  SLR = Spectrin Like Repeat 
Domain, CT = Carboxy Terminal Domain, green = SNP, red = missense 
mutation.  Curves partitioned into a single transition unfolding (upper curves) or a 
two transition unfolding (lower curves).  
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Figure 2.4:  Average size and polydispersity of missense mutations in 
Dp260  (A) Z-average radius for each Dp260 isoform protein measured by 
Dynamic Light Scattering.  Mean value and standard deviation bars are shown 
for a technical triplicate, units in nm of hydrodynamic radius.  None show an 
increase in particle size by an order of magnitude above WT protein.  (B) 
Polydispersity Index measured on a scale from 0 to 1, where 0 indicates 
complete monodispersity and 1 a completely heterogeneous mixture.  WT protein 
has a PdI within quality control standards.  Green = SNP, red = missense 
mutation. 
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Figure 2.5:  Solubility and expression levels of missense mutations in full-
length Dp427  (A) Representative immunoblot analysis of soluble fraction (S) 
and insoluble fraction (I) from Sf9 cell lysates infected with baculovirus 
expressing the full-length isoform of dystrophin with indicated amino acid change.  
(B) Quantification of percent solubility by calculating soluble band values divided 
by soluble and insoluble band totals from immunoblots depicted in (A).  n=3.  Red 
= disease associated, green = SNP, none were significantly different than WT.  
(C) Quantification of the total protein expressed in soluble and insoluble band 
values normalized to WT total on each blot.  n=3.  Significantly decreased (‡ 
p<0.05) (* p<0.0001)  (D) Coomassie-stained acrylamide gel of total purified 
protein.  Protein was concentrated and then measured by A280.  6µg of each 
sample was loaded.  
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Figure 2.6:  Secondary structure and stability, tertiary stability, and average 
size of missense mutations in Dp427  (A) Circular Dichroism absorption 
spectra of each Dp427 purified protein.  All spectra display molar ellipticity 
minima at 208 and 222nm indicative of a highly alpha-helical protein.  (B) 
Circular Dichroism melt curves obtained by monitoring absorption values at 
222nm over temperature gradient of 20-90°.  Values are normalized from 0-1 
fraction unfolded.  NT = Amino Terminal, SLR = Spectrin Like Repeat Domain, 
CT = Carboxy Terminal Domain, green = SNP, red = missense mutation.  Unlike 
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the Dp260 isoform, WT unfolds with a single transition, making it distinguishable 
from proteins with a more linear unfolding (L54R and C3207R).  (C) Differential 
Scanning Flourimetry monitored at 610nm over a temperature range of 20-90°.  
Fluorescent values are normalized from 0-1 fraction unfolded.  NT = Amino 
Terminal Domain, SLR= Spectrin Like Repeat Domain, CT = Carboxy Terminal 
Domain.  WT protein shown in black, disease associated missense mutations in 
red, and SNPs in green.  All amino acid changes align with WT in the SLR and 
CT.  L54R and L172H in the NT, however, show a left shift indicating instability or 
a partial unfolded state at ambient temperature.  (D) Calculated z-average for 
each full-length Dystrophin protein measure by Dynamic Light Scattering.  Mean 
value and standard deviation bars are shown for a technical triplicate, units in nm 
of hydrodynamic radius.  Z-average values are relatively larger than those for 
Dp260 as is expected.  None show an increase in particle size by an order of 
magnitude above WT protein.  (E) Polydispersity Index measured on a scale 
from 0 to 1, where 0 indicates complete monodispersity and 1 a completely 
heterogeneous mixture.  WT protein has a PdI within quality control standards, 
and all other proteins have a similar value.   
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Chapter 3 
 
 
 A Cell Culture Model of Missense  
Mutations in Dystrophin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow cytometry analysis was performed with the assistance of the University of 
Minnesota flow core technicians.  All other cloning, cell culture, and analyses 
were performed by Dana Talsness. 
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Summary 
 Duchenne and Becker muscular dystrophies are genetic disorders that 
cause muscle weakness and atrophy primarily in male patients with a mutation in 
their gene encoding the protein dystrophin.  In several cases the causative 
mutation is a single nucleotide change, or missense mutation, which results in an 
amino acid substitution in the protein.  A previous study characterized a set of 
missense mutations found in the amino terminal, first actin-binding domain of 
dystrophin and found each caused protein misfolding and thermal instability in 
vitro.  To determine the cellular consequences of in vitro instability, we generated 
four transgenic C2C12 myoblast cell lines expressing full-length dystrophin with 
coding sequence for WT, missense mutations L54R or L172H, or single 
nucleotide polymorphism I232M.  Quantitative RT-PCR and western blot analysis 
revealed that full-length dystrophin protein levels were decreased for both 
mutants relative to respective transcript levels when compared to WT.  In 
addition, it was possible to increase mutant dystrophin levels with several 
different small molecule therapeutics aimed at increasing osmotic stability, up-
regulating the heat shock pathway, or inhibiting the proteasome.  The C2C12 
myoblast models indicate that mutant dystrophin is targeted to the proteasome 
for degradation and represent a system for potential discovery of personalized 
therapeutics. 
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Introduction 
 Given that dystrophin is a structural protein without enzymatic activity and 
given the in vitro evidence in Chapter 2, it is likely that missense mutations would 
lead to protein instability in the cell as seen by either aggregation or degradation 
of the protein.  The cell has several pathways for dealing with unstable proteins 
including the heat shock pathway.  The heat shock pathway was first discovered 
as a set of proteins that were up-regulated in response to a transient increase in 
temperature of the cell (Ritossa, 1962; Ashburner and Bonner, 1979).  Further 
investigation has revealed these proteins are molecular chaperones which aid in 
the initial folding of proteins as well as the refolding of misfolded proteins, 
collectively known as the heat shock proteins (HSPs), and transcribed by the 
heat shock factors (HSFs) (Bozaykut et al., 2014).  There are several families of 
HSPs including the high molecular weight, ATP-dependent HSPs: Hsp90, Hsp70, 
and Hsp40; as well as the small, ATP-independent HSPs such as Hsp27.   
 Hsp90s are responsible for binding to recently folded proteins and 
maintaining them in a folded state.  When not bound to a client protein, Hsp90s 
bind to and inhibit the transcription factor HSF1, thereby acting as a negative 
regulator of the heat shock pathway (Akerfelt et al., 2010).  Additionally it has 
been shown that the phosphorylation of Hsp90s can affect their affinities for client 
proteins (Bozaykut et al., 2014).  Hsp70s facilitate both de novo folding and 
refolding of misfolded proteins in the cell utilizing an ATP/ADP dependent cycle 
of binding and unbinding to substrates (Mayer and Bukau, 2005).  Their functions 
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are ubiquitous and necessary for protein quality control in the cell.  Hsp40s 
recognize unfolded protein and transfers them to Hsp70, thereby acting as a co-
chaperone (Summers et al., 2009).  Hsp27s can form large oligomers and 
generally function to prevent aggregation of misfolded proteins (Bozaykut et al., 
2014).  Phosphorylation of Hsp27s favors small oligomers and decreases its 
ability to prevent aggregation (Lanneau et al., 2010).  Together, all of the HSPs 
work to properly fold proteins.  When a protein is considered beyond repair (by 
unknown mechanisms) the same Hsp40 and Hsp70 chaperones that attempted 
refolding will then facilitate the entrance of the protein into the ubiquitin 
proteasome system (Shiber and Ravid, 2014). 
 The cell has multiple methods for eliminating proteins that are not properly 
folded by the translational chaperones and the heat shock pathway, including the 
ubiquitin proteasome system (UPS).  The UPS utilizes a cascade of conjugation 
to ubiquitin, a small 76 amino acid protein used as a post-translational 
modification.  Ubiquitin is highly conserved in all eukaryotes and expressed in 
every cell, hence the name.  In the first step of the UPS cascade one of eight E1 
activating enzymes utilizes energy from ATP to form a thioester bond to ubiquitin 
(Schulman and Harper, 2009).  Ubiquitin is then passed to a pathway specific E2 
conjugating enzyme; there are approximately 40 known E2 ligases (Ye and 
Rape, 2009). They determine both ubiquitin chain elongation and type of 
ubiquitin linkage on the protein substrate.  The E2 conjugating enzyme then 
binds to an E3 ligase of which there are over 600 (Deshaies and Joazeiro, 2009).  
  58 
Each E3 ligase has specific protein substrates to which it binds.  When the E3 
binds to an E2 complexed with ubiquitin, the ubiquitin is transferred from E2 to 
the substrate.  Therefore in the ubiquitin cascade, the E3 ligase provides the 
ultimate specificity of the system. When 4 ubiquitins have been transferred to a 
substrate, in a K48-linked chain, the protein is targeted for degradation by the 
proteasome (Thrower et al., 2000). 
 The proteasome is made of two major subcomplexes: the 20S core which 
contains the proteolytic sites and the 19S regulatory unit that caps either one or 
both ends of the 20S core (reviewed in Glickman & Ciechanover 2002).  
Altogether this protein complex is about 2.5MDa (26S).  The 19S regulatory unit 
is composed of at least 18 subunits and functions to recognize ubiquitinated 
substrates and mediate their transfer into the 20S core.  The 20S complex is a 
hollow core made of 4 stacked rings from top to bottom α, β, β, α.  The β rings 
each contain three proteolytic sites facing the interior of the cylinder which have 
caspase-, trypsin-, and chymotrypsin-like activity respectively (Weathington and 
Mallampalli, 2014).  Through these three protease-like activities, the 20S core is 
able to effectively degrade all protein substrates. The proteasome utilizes ATP 
hydrolysis to cleave proteins into 3-23 amino acid peptides which can then be 
further degraded by proteases in the cell (Kisselev et al., 1998), effectively 
eliminating and recycling the targeted protein. 
 There are several examples of missense mutations in proteins other than 
dystrophin being studied in cell culture models.  One such example is a study of 
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missense mutations in the gene EPM2A encoding the protein laforin which cause 
Lafora’s Disease (Liu et al., 2009).  They expressed EPM2A with several 
different missense mutations in both HEK293 and NIH3T3 cell lines and found 
that all mutations caused a decrease in the soluble protein levels of laforin.  
Another group analyzed missense mutations in the protein SIMPLE that cause 
Charcot-Marie-Tooth Disease (Lee et al., 2011).  SIMPLE is a membrane bound 
protein and missense mutations caused both mislocalization and aggregation of 
the protein when expressed in HeLa cells.  Recently there was a study of 
missense mutations in the protein B3GNT1, a type II transmembrane protein 
which localizes to the Golgi and causes Walker-Warburg Syndrome (Buysse et 
al., 2013).  When mutant B3GNT1 was expressed in PC3 cells, it localized 
correctly to the Golgi, but it impaired the glycosyltransferase enzymatic activity of 
the protein.  These cell culture models have shown that missense mutations can 
lead to disease through various mechanisms.  
 There are relatively few successes to study recombinant dystrophin in cell 
culture models.  The short isoform Dp71 has been transiently expressed in 
HEK293 and C2C12 cell lines in order to study the effect of alternate splicing on 
localization (González et al., 2000).  Studies have transfected cells with AAV 
constructs containing small, truncated versions of dystrophin to prove the 
constructs would express before using them in animal transfection experiments 
(Fabb et al., 2002).  A micro-dystrophin construct (144 kDa) was transiently 
transfected into primary mouse myoblasts and C2C12 cells and was shown to 
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localize to the plasma membrane of cells upon differentiation to myotubes 
(Draviam et al., 2006).  Another study transiently transfected HEK293 cells with 
several Dp71-like constructs: WT and three missense mutations located in the 
ZZ domain of the cysteine rich region (Vulin et al., 2014).  It was found that two of 
the missense mutations (C3313Y and C3340Y) dramatically decreased the levels 
of soluble Dp71 protein expressed in the cells, while one mutation (D3335H) 
expressed at WT levels.  Mutation D3335H was determined to have decreased 
binding affinity to β-dystroglycan.  To date there have been no cell line models 
stably expressing transgenic, full-length dystrophin.  
 One of the best candidate cell lines to use for expressing full-length 
dystrophin is the C2C12 line.  C2C12 is a mouse myoblast cell line, first 
immortalized as a control population in order to study dystrophic cells (Yaffe and 
Saxel, 1977).  Karyotype analysis of C2C12 cells reveals tetraploidy with an 
average of 80 chromosomes per genome (Chang et al., 2007).  The cells are 
female in origin with four X-chromosomes, two of which are inactivated (Casas-
Delucchi et al., 2011); this is important to note given that the mouse DMD gene is 
encoded on the X-chromosome similar to humans.  C2C12 cells can be cultured 
indefinitely as myoblasts with splitting at subconfluency, or they can be 
differentiated into terminal myotubes with reduced serum media.  Microarray 
analyses comparing C2C12 cells before and after differentiation into myotubes 
reveal over 1500 transcript expression changes including several transcription 
factors and genes responsible for chromatin remodeling (Delgado et al., 2003).  
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LC-MS proteomic analysis of differentiating C2C12 showed similar changes in 
proteins linked to cell adhesion, intracellular signaling, gene expression, 
metabolism, and muscle contraction.  Overall C2C12 cells serve as an easy to 
use and well-studied skeletal muscle cell culture system. 
 To determine the cellular fate of dystrophin proteins harboring missense 
mutations, we engineered two candidate mutations, L54R and L172H into full 
length dystrophin and expressed them in C2C12 mouse myoblast cells with the 
use of the PiggyBac transposon system.  In this model system we demonstrated 
that mutant dystrophin is misfolded and degraded by the proteasome to a degree 
that is proportional to the severity of disease seen in the patients harboring these 
mutations.  Our results reveal the cellular consequences of a protein that is 
unstable in vitro as well as potential avenues of therapeutic treatment.  
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Materials and Methods 
Cloning 
Full-length mouse dystrophin cDNA (WT, and all missense mutations) was 
subcloned into the Gateway system Entry vector as described in Chapter 2. The 
mammalian expression vector PiggyBac-CMV-MCS-EF1-Puro (System 
Biosciences) was purchased and then a destination cassette was subcloned into 
the MCS in order to adapt it to the Gateway® system.  The dystrophin cDNA was 
recombined from the entry vector into the newly made PiggyBac™ destination 
vector using Life Technology’s Gateway® LR Clonase® (Hartley, 2000).  
Cell transfection and stable line selection 
The PiggyBac destination vector with inserted dystrophin cDNA along with the 
Super PiggyBac Transposase vector (System Biosciences PB200PA-1) was 
electroporated into C2C12 cells (ATCC CRL-1772) using a Nucleofector™ 2b 
(Lonza) device with the accompanying C2C12 kit (Amaxa VCA-1003).  After 
electroporation cells were cultured for 48 hours.  Then cells were split 1:15 into 
media containing 2ug/mL puromycin and cultured for 2 weeks until colonies of 
cells were visible to the naked eye.  Individual colonies were selected, cultured, 
and then screened for similar levels of transgene insertion by gDNA qPCR 
described below.   
Cell culture and differentiation 
C2C12 (ATCC CRL-1772) transgenic cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (Gibco) supplemented with 10% Fetal Bovine Serum 
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(Gibco), 1% penicillin/streptomycin cocktail (Hyclone 15290), and 0.1% fungizone 
(Gibco); and grown at 37°C, 5% CO2.  Cells were always grown to 80% 
confluency and then either split for further subculturing or used for an analysis.  
C2C12 lines were differentiated by growing cells to 80% confluency and then 
changing the media to DMEM supplemented with 2% Horse Serum (Gibco) and 
penicillin/streptomycin and fungizone.  Differentiation media was changed every 
other day until full differentiation was reached 7 days after initiation.   
gDNA qPCR 
Cells were collected and gDNA was isolated with GenElute™Mammalian 
Genomic DNA Miniprep kit (Sigma-Aldrich G1N70). The DNA was then amplified 
by primers within the CMV promoter region of the transgene: forward 
[GGCCTCCAAGGCCACTAGTAT] and reverse [TCCACGCCCATTGATGTACT] 
using SsoAdvanced™ Universal SYBR® Green Supermix (Biorad 172-5270). All 
measurements were relative to the reference gene ADH: forward 
[GCACTGCGGGAAAAGTAAGG] and reverse [TAGCAGGTCAAGCTGTGCTC]. 
Measurements were collected with the C1000 Touch Thermal Cycler (Biorad) 
and analyzed with the CFX Manager software (Biorad).   
RT-qPCR 
Cells were collected and RNA isolated with Aurum™ Total RNA Mini Kit (Biorad 
732-6820). Total RNA was reverse transcribed into cDNA using the iScript™ 
Advanced cDNA Synthesis Kit (Biorad 170-8843). cDNA was amplified with 
primers within the GFP sequence in order to detect on transgenic dystrophin 
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transcript: Forward [TCCGCCATGCCCGAAGGCTA] and Reverse 
[CCGTTCACCAGGGTGTCGCC] using SsoAdvanced™ Universal SYBR® Green 
Supermix (Biorad 172-5270). All measurements were relative to reference 
transcript Hprt: Forward [CCCTGGTTAAGCAGTACAGCCCC] and Reverse 
[GGCCTGTATCCAACACTTCGAGAGG]. Measurements were collected with the 
C1000 Touch Thermal Cycler (Biorad) and analyzed with the CFX Manager 
software (Biorad).  
Western blot analysis 
Cells were collected and lysed with RIPA buffer [10 mM Tris-Cl (pH 8.0), 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 
140 mM NaCl] with added protease inhibitors [100nM Aprotonin, 10mg/ml E-64, 
100µM Leupeptin, 1mM PMSF, 1µg/ml Pepstatin] proportional to mass of cell 
pellet.  Equal volumes of lysate were then separated by electrophoresed at 150V 
for 1 hour, then transferred to PVDF membrane at 100V/0.7Amp for 1 hour.  
Membranes were blocked in either [5% non-fat milk in phosphate buffered saline 
0.1% Tween solution] or [5% Bovine Serum Albumin in tri buffered saline 0.1% 
Tween solution] depending on the primary antibody for 1 hour. Primary 
antibodies used were anti-GFP (Cell Signaling 2956) at 1:1000, anti-pan actin C4 
( ) at 1:5000, anti-Desmin D93F5 (Cell Signaling 5332) at 1:1000, anti-Hsp40 
C64B4 (Cell Signaling 4871) at 1:1000, anti-Hsp70 (Cell Signaling 4872) at 
1:1000, anti-Hsp90 (abcam 19021) at 1:1000, anti-Phosph-Hsp90α (Cell 
Signaling 3488) at 1:1000, anti-Phospho-Hsp27 (Cell Signaling 9709) at 1:1000, 
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and anti-Ubiquitin P4D1 (Cell Signaling 3936) at 1:1000.  Blots were ten 
incubated in secondary antibodies anti-mouse or anti-rabbit IgG Dylight® 800 
(Cell Signaling) at 1:10,000 in blocking buffer.  Secondary antibody signal was 
visualized on Licor’s Odyssey® Infrared Imaging System and band density 
calculated with Odyssey Software v2.1.   
Small molecule treatments 
Trehalose (Sigma Aldrich T0167) was prepared as a stock solution at 100mM in 
H2O; cells were treated at working concentrations for 24 hours.  TMAO 
[Trimethylamine N-oxide] (Acros Organics 421890250) was prepared as a stock 
solution at 1M in H2O; cells were treated at working concentrations for 24 hours. 
Betaine (Alfa Aesar B24397) was prepared immediately before use at 400mM in 
cell culture media; cells were treated with working concentrations for 24 hours. 
Celastrol (Sigma Aldrich C0869) was prepared as a stock solution at 10mM in 
DMSO; cells were treated at working concentrations in equal volumes of DMSO 
for 18 hours. BGP-15 (Sigma Aldrich B4813) was prepared as a stock solution at 
10mM in H2O; cells were treated at working concentrations in equal volumes of 
H2O for 18 hours. Gedunin (Santa Cruz 203867) was prepared as a stock 
solution at 10mM in DMSO; cells were treated at working concentrations in equal 
volumes of DMSO for 18 hours. MG-132 (American Peptide 81-5-15) was 
prepared as a stock solution at 1mM in DMSO; cells were treated at working 
concentrations in equal volumes of DMSO for 18 hours. MG-262 (A.G. Scientific 
Z-1003) was prepared as a stock solution at 100µM in DMSO; cells were treated 
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at working concentrations in equal volumes of DMSO for 18 hours. Bortezomib 
(Cell Signaling 2204) was prepared as a stock solution at 10mM in DMSO; cells 
were treated at working concentrations in equal volumes of DMSO for 18 hours. 
Epoxomicin (Sigma Aldrich E3652) was prepared as a stock solution at 1mM in 
DMSO; cells were treated at working concentrations in equal volumes of DMSO 
for 18 hours.  
Flow Cytometry 
Cells were dislodged from the cell culture plate with TrypLE Express™ (Gibco) 
and resuspended in Phosphate Buffered Saline (Gibco) supplemented with 
1%FBS.  Cells were incubated with SYTOX® Red Dead Cell Stain (Invitrogen 
S34859) per the manufacturer’s instructions.  Measurements were taken at the 
University of Minnesota’s Flow Core facility on an Accuri C6 Flow cytometer (BD 
Biosciences).  Cells were gated for forward and side scatter, against positive 
SYTOX® staining, and measured for GFP fluorescence.  All analysis was 
performed on FloJo v7.6 software. 
Statistics 
All statistical calculation were performed with JMP® statistics software.  Data are 
presented as mean ± standard error of the mean in bar graphs.  To determine 
significance for all data with three or more groups, one-way ANOVA analysis was 
performed with α=0.05.  Upon significance of the ANOVA, the Tukey post hoc 
test was performed with all pairs of data at α=0.05. 
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Results 
 In order to understand the cellular consequences of missense mutations in 
dystrophin, stably-expressing transgenic mouse myoblast C2C12 cell lines were 
generated with the PiggyBac™ transposon system (Figure 3.1).  Two disease-
causing missense mutations were investigated: L54R representing severely 
affected Duchenne patients and L172H representing mildly affected Becker 
patients.  In addition to a WT dystrophin transgenic line, a single nucleotide 
polymorphism (SNP) found in the population, I232M, was generated as a control. 
In the range of 3-5 clonal colonies were generated for each genotype and 
screened for equivalent levels of transposon integration.   
 The selected myoblast cell lines expressing full-length dystrophin were 
analyzed for genomic transgene levels by qPCR (Figure 3.2A). As expected the 
non-transgenic C2C12 line had no incorporation of transgene and each of the 
other lines showed similar levels. The L172H line was found to have statistically 
higher incorporation of transgene, approximately 2-fold that of the WT line.  A 2-
fold difference is small compared to the orders of magnitude range that was 
measured during the screening process for stable lines.  It was determined that 
the myoblast lines generated were sufficient to act as a model of different 
missense mutations in dystrophin given that quantitation corrected for differences 
in apparent genome copy number. The transcript levels expressed from the 
transgenes were then measured by RT-qPCR (Figure 3.2B). As expected based 
on gDNA analysis, L172H and now I232M had statistically higher levels of 
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dystrophin mRNA.  
 Each cell line was then analyzed for full-length GFP-dystrophin fusion 
protein (455 kDa) by Western blot analysis (Figure 3.2C).  It was observed that 
the two disease-causing mutations, L54R and L172H, showed decreased protein 
expression.  Quantification of three separate lysates revealed both missense 
mutations significantly decreased the steady-state level of dystrophin while the 
SNP I232M increased it significantly.  Due to the differences in transgene and 
transcript levels (Figure 3.2A&B) inherent to transgenic models, the protein levels 
were normalized relative to their respective transcript level (Figure 3.2E). The 
steady-state ratio of protein:mRNA for L54R was only 13% of WT protein and 
L172H expressed 46% of WT protein while I232M was comparable to WT.  
These data indicate that the severity of disease found in patients inversely 
correlates with the level of mutant dystrophin protein.   
 A benefit of utilizing the C2C12 myoblast cell line is its facile differentiation 
into myotubes.  We wanted to determine whether differentiation into myotubes 
had any affect on the steady-state levels of the transgenic dystrophin due to 
increased presence of normal binding partners or any other myotube specific 
mechanism. Myoblast cells were switched to a low serum media and analyzed at 
days 0, 3, and 7 post-differentiation initiation. Transcript analysis of desmin, a 
marker of differentiation (Figure 3.3A), revealed an apparent increase from day 0 
to day 7 for each of the lines analyzed.  There was no difference in degree of 
differentiation between non-transgenic, WT, or mutant. Transcript analysis of the 
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GFP-dystrophin transgene (Figure 3.3B) showed there was no stabilization of the 
transcript upon differentiation for either WT or mutant dystrophin.   
 Western blot analysis of desmin protein (Figure 3.3C) confirmed the RT-
qPCR analysis.  Abundance of desmin protein (Figure 3.3D) increased from day 
0 to day 7 for each of the cell lines analyzed. For both WT and L54R there were 
statistically significant increases in desmin protein from day 0 to day 7, indicating 
that a mutation in dystrophin apparently had no effect on the ability of the C2C12 
cells line to differentiate.  The GFP-dystrophin fusion protein was also measured 
by Western blot analysis (Figure 3.3C) and three separate differentiations 
quantified (Figure 3.3E).  The WT dystrophin line saw an apparent increase in 
protein levels, but it was not statistically significant.  Most importantly, despite a 
trend of increasing L54R transcript (Figure 3.3B) upon differentiation, there was 
no increase in protein (Figure 3.3E).  These results indicate that the mutant 
protein was not stabilized upon differentiation of myoblasts into myotubes. 
 Given that previous studies have shown L54R and L172H are thermally 
unstable in vitro (Henderson et al. 2010, Chapter 2) and that there is less steady-
state levels of protein with these mutations (Figure 3.2), we hypothesized that 
L54R and L172H mutant dystrophins are misfolded in C2C12 myoblasts. The 
heat shock system of the cell is known to up-regulate heat shock proteins in 
response to misfolded protein.  Therefore we assessed by western blot analysis 
whether expression of mutant dystrophin caused an increase in heat shock 
protein expression (Figure 3.4A). Quantification revealed that there were few 
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significant increases of the various heat shock proteins in the lines expressing 
mutant dystrophin compared to WT dystrophin. (Figure 3.4B).  There was a 
significant increase in Hsp40 and a significant decrease in phosphorylated Hsp27 
measured in the L172H line.  Given that L172H is the mutation associated with 
mild muscular dystrophy symptoms, the apparent changes are likely stochastic.  
Cell culture experiments in which the whole culture is actually shocked with heat 
show rapid and dramatic increases in the heat shock pathway proteins 
(Ashburner and Bonner, 1979), which is not unexpected given that a majority of 
the proteome is now misfolded.  By comparison, only one protein out of the 
whole proteome is potentially misfolded in our cell line models, therefore it is not 
surprising that we did not see a large increase in heat shock protein levels. In 
fact the lack of up-regulation offers a possible avenue of therapeutics that could 
force up-regulation of the heat shock pathway and lead to stabilization of the 
dystrophin protein. 
 We screened three categories of small molecules with promise of 
increasing mutant dystrophin levels by various mechanisms.  The first category 
of small molecules screened was osmolytes (Figure 3.5A), which are thought to 
populate the interior of the cell at high concentrations enhancing thermodynamic 
stability of proteins (Kumar, 2009; Arakawa et al., 2006). The osmolyte trehalose 
is commonly synthesized by bacteria and yeast under thermodynamic stress, has 
been found to alleviate symptoms in models of protein misfolding (Castillo et al., 
2013; Tanaka et al., 2004), and is even sold in nutrition supplement stores.  
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When applied to the mutant L54R line at the highest concentration of 500mM 
cells did not survive.  At lower concentrations there was no apparent increase in 
dystrophin protein levels.  Another osmolyte, TMAO [Trimethylamine N-oxide], is 
found in salt water animals such as sharks and rays to stabilize proteins against 
the osmotic pressure (Yancey et al., 1982) and was applied to the mutant 
dystrophin cell line.  Like trehalose, very high concentrations killed the cells and 
lower concentrations had no effect on protein levels.  Lastly betaine was 
screened for effect; betaine is an osmolyte found in the kidney of mammals 
(Burg, 1995).  At the highest dose of 400mM there was a visible increase in 
mutant dystrophin protein, which is a proof of principle result that osmolytes can 
stabilize full-length dystrophin protein. The extremely high doses required, 
however, make this a null option for therapeutic treatment. 
 The second class of small molecules screened was the heat shock 
activators (Figure 3.5B).  The first compound, celastrol, is a natural product 
isolated from the plant family Celastraceae which activates the conserved heat 
shock factor 1 (HSF1) which in turn transcribes several downstream components 
of the heat shock pathway (Trott et al., 2008; Westerheide et al., 2004). At 
tolerated doses up to 1µM there was no increase in mutant dystrophin protein. 
Another heat shock activator, BGP-15, specifically induces one of the heat shock 
proteins, HSP72, and has been shown to alleviate symptoms in models of both 
diabetes and muscular dystrophy (Chung et al., 2008; Gehrig et al., 2012). 
Unfortunately we saw no direct molecular effect on dystrophin protein levels at 
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tolerated doses up to 50µM. The third heat shock activator screened was 
gedunin, a product isolated from the tree species Azadirachta indica which binds 
to and inhibits Hsp90 thereby releasing bound HSF1 for transcriptional activity 
(Brandt et al., 2008; Neef et al., 2011).  Concentrations between 10 and 80µM 
were found to have a dose-response relationship with dystrophin protein.  These 
data indicate that it is possible to pharmacologically activate the heat shock 
system of the cell which then facilitates the chaperone-mediated stabilization of 
mutant dystrophin. 
 Lastly proteasome inhibitors were screened in an attempt to find more 
small molecules that can increase the levels of mutant dystrophin protein (Figure 
3.5C). Both the classic proteasome inhibitor MG132 and its derivative MG262 
had a robust effect on the mutant dystrophin in a dose-response relationship, 
indicating that 1) the proteasome is at least one of the mechanisms by which 
mutant dystrophin is degraded in the cell and 2) proteasome inhibitors are a 
viable option for molecular correction of Duchenne muscular dystrophy caused 
by missense mutations.  Several proteasome inhibitors are currently in clinical 
trials for treatment of multiple myeloma including bortezomib and derivatives of 
epoxomycin both of which we also screened. Bortezomib is a member of the 
boronic acid class of proteasome inhibitors and inhibits the chymotrypsin-like site 
of the proteasome (Kisselev et al., 2012). Recently, a study demonstrated its in 
vivo ability to increase levels of missense mutated dysferlin (Azakir et al., 2014). 
Bortezomib showed a strong dose-response effect on missense mutated 
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dystrophin as well (Figure 3.4C).  Epoxomycin is an epoxyketone and also 
targets the chymotrypsin-like site of the proteasome (Kisselev et al., 2012); its 
derivative, carfilzomib, is currently in clinical trials for multiple types of cancers. 
Epoxomycin also had a robust effect on the level of dystrophin protein in our cell 
culture model.  
 To investigate further the effects of three positive hits from the screen 
(gedunin, bortezomib, and epoxomicin), both L54R and L172H cells were treated 
in parallel with each of the small molecules at a submaximal dose determined in 
the screen (Figure 3.6).  Western blot analysis of the full-length GFP-dystrophin 
fusion protein (Figure 3.6A) shows marked increases in the L54R for all three 
small molecules.  The line L172H without treatment has a higher level of mutant 
dystrophin protein, yet an increase is still visible for both bortezomib and 
epoxomicin.  When the proteasome is inhibited there is an accumulation of 
ubiquitinated proteins that are being targeted to the proteasome for degradation, 
therefore we blotted for ubiquitin in each of the small molecule treatments (Figure 
3.6A bottom panel). Not surprisingly the two proteasome inhibitors show a large 
increase in ubiquitination across the proteome.  The heat shock activator gedunin 
had a similar effect on ubiquitination in the cell, emphasizing the close 
connection between the heat shock pathway and the ubiquitin-proteasome 
pathway, and corroborating previous studies that have found Hsp90 inhibition 
increases the ubiquitination state of the proteome (Basak et al., 2008). 
 The transgenic myoblast models were designed with a GFP-dystrophin 
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fusion construct in the anticipation that they will be used in the future for high-
throughput screens, monitoring GFP fluorescence by flow cytometry. The 
functionality of this approach was validated (Figure 3.6B). The non-transgenic 
C2C12 cells were used as a negative control to gate for positive GFP 
fluorescence.  The WT Dystrophin cell line showed a positive population shift for 
GFP fluorescence compared to non-transgenic cells which correlates with the 
Western blot analysis in Figure 3.2C. It is important to note that the fluorescent 
signal is much lower than that seen in cells expressing GFP alone; GFP fused to 
a 427 kDa protein gives a low yet still detectable signal.  The two missense lines 
were then treated with submaximal doses of the three effective small molecules 
and GFP fluorescence measured by flow cytometry. As expected the L54R cell 
line when untreated had very low fluorescent signals with only 2.39% of cells 
above the threshold of detectable signal relative to non-transgenic.  Upon 
treatment with gedunin, bortezomib, or epoxomicin 86.6%, 91.2%, and 82.9% of 
cells had positive GFP signal respectively, again corresponding to Western blot 
results (Figure 3.5 and Figure 3.6A). The L172H line without treatment had 
approximately the same percentage of positive GFP cells (28.8%) as the WT, but 
with a lower average intensity.  Upon treatment with the three small molecules, 
cells positive for the GFP-dystrophin protein increased to 80.7%, 95.6%, and 
84.2%.  Figure 3.6C shows the same data in a histogram of percent maximal 
signal for each treatment group.  It is clear that each of the three small molecule 
treatments detectably increases GFP fluorescent signal.  These results both 
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confirm the findings by western blot analysis and validate flow cytometry as a 
method for high throughput screening of these cell models. 
 In addition to monitoring the ubiquitination state of the cell after treatment 
with the three small molecules, we wanted to see their effect on the heat shock 
pathway of the cells (Figure 3.7).  Both the L54R and L172H cell lines were 
treated with submaximal doses of gedunin, bortezomib, and epoxomicin and then 
blotted for the same heat shock proteins as in Figure 3.4.  There were significant 
increases in the heat shock proteins Hsp70, Hsp90P, and Hsp27P compared to 
the untreated control cells.  An increase in HSPs would be expected from both 
the heat shock activator, gedunin, and the proteasome inhibitors given that when 
the proteasome is no longer functioning, there will be more misfolded protein 
present in the cell and therefore it is likely to see an increase in the heat shock 
pathway.  The largest increases in the heat shock proteins were seen with the 
small molecule epoxomicin likely because it was simply the most potent of the 
three at their respective given dosages. 
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Discussion 
 We report here the generation of a myoblast cell culture model stably 
expressing full-length dystrophin protein variants of WT, L54R, L172H, and 
I232M.  The missense mutation associated with the severe symptoms of 
Duchenne Muscular Dystrophy, L54R, had steady-state levels of dystrophin 
protein at less than 10% of WT levels; while the missense mutation associated 
with the mild symptoms of Becker Muscular Dystrophy, L172H, expressed at 
approximately 40% of WT.  The data suggest that the severity of disease is 
inversely correlated with the level of dystrophin protein in the cell. 
 In Chapter 2 and in a previous publication (Henderson et al., 2010) we 
demonstrated that these mutations cause thermal instability of dystrophin protein.  
It is now apparent that this instability in vitro leads to a degradation of the protein 
by the proteasome in the cellular environment.  Proteins are targeted to the 
proteasome for different reasons: either they have served their function and now 
need to be removed such as the cyclins during the cell cycle, or they are 
misfolded beyond the repair of the heat shock pathway.  For a given WT protein, 
it is estimated that up to 30% of the translated protein is sent to the proteasome 
due to lack of native folding (Wang et al., 2013).  When a protein is mutated, 
however, that percentage increases to a point that causes an insufficiency in the 
cell.  Our two candidate mutations have shown that the more destabilizing the 
amino acid change, the more misfolding and degradation there will be for the 
dystrophin protein and consequently more severe symptoms in patients. 
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 In our proof-of-concept screen to increase the levels of dystrophin there 
was at least one positive hit from each of the three categories: osmolytes, heat 
shock activators, and proteasome inhibitors.  The osmolyte betaine was able to 
increase mutant dystrophin protein at very high concentrations.  It is not 
surprising that the one osmolyte that is naturally found in mammals was the only 
one to have effect, but the extreme dosage that would be required makes any 
type of potential therapy with this small molecule less feasible.  The heat shock 
activator gedunin had a positive effect on dystrophin protein levels at moderate 
concentrations.  Even though it did not inhibit the proteasome, it still increased 
levels of ubiquitination in the cell, which further speaks to how closely related the 
heat shock pathway and the ubiquitin proteasome system are.  The efficacy of 
gedunin supports that heat shock activators may be useful to treat DMD patients 
with missense mutations and a broader screen may identify heat shock activators 
that are effective at lower doses that may be better tolerated by patients. 
 When the L54R line was treated with any one of a number of proteasome 
inhibitors, protein levels were restored to WT levels indicating that the majority of 
the mutant protein is being degraded by the proteasome, differentiating it from 
mutations that cause aggregation of proteins like those found in Alzheimer’s and 
Huntington’s.  In protein degradation diseases there is often a gain-of-function 
toxic effect caused by the aggregates and therefore treatment is two-fold: 
removing the aggregate and replacing with a functional protein. The L54R and 
L172H mutant dystrophins expressed in myoblasts are degraded by the 
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proteasome and therefore treatment is potentially one-fold: stop the degradation 
of the mutant protein.  Further work will be needed to determine if the protein 
inhibited from being degraded is fully or partially functional, as the functionality of 
dystrophin is not measurable in a cell culture system.    
 In summary, our new C2C12 cell models suggest the molecular 
mechanism of decreased dystrophin expression in patients with two different 
missense mutations.  In addition, we have generated an efficient model system 
for large scale screens of other small molecule libraries as well as siRNA knock-
down libraries. 
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Figure 3.1: Expression construct and experimental concept 
Full-length, mouse dystrophin cDNA was subcloned with an N-terminal GFP 
protein under a CMV promoter.  This expression cassette was a part of the 
PiggyBac vector which also expressed a puromycin resistance gene under a 
EF1α promoter.  The PiggyBac transposon vector with dystrophin insert was co-
transfected with the PiggyBac transposase vector by electroporation into C2C12 
cells.  After 48 hours, cells were selected for transposon insertion into the 
genome with puromycin.  Clonal lines were screened for similar levels of 
transgene incorporation.   
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Figure 3.2:  Expression levels of transgenic dystrophin in myoblast cell 
lines. (A) qPCR analysis of genomic DNA.  Sequence amplified within CMV 
promoter to measure degree of transgene insertion into genome. n=3 separate 
sample collections and gDNA isolations. Measurements relative to reference 
gene ADH and normalized to a WT sample. ANOVA F<0.0001, ✱p<0.05 
compared to WT. (B) RT-qPCR of total RNA.  Sequence amplified within GFP 
sequence to measure levels of transgenic transcript. n=3 separate sample 
collection, RNA isolation, and reverse transcription.  Measurements relative to 
reference transcript Hprt and normalized to a WT sample. ANOVA F<0.0001, 
✱p<0.05 compared to WT. (C) Representative Western blot of cell lysate. Blot 
was probed with GFP primary antibodies to detect the transgenic GFP-
Dystrophin fusion protein (455 kDa).  (D) Quantification of n=3 separate cell lyses 
and Western blot analyses. Measurements normalized to WT sample on each 
blot. ANOVA F<0.0001, ✱p<0.05 compared to WT. (E) The ratio of the 
normalized protein levels to the normalized transcript levels.   
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Figure 3.3:  Differentiation of stable transgenic cell lines.  (A&B) RT-qPCR 
analysis of cell lines differentiated for 0, 3, and 7 days in reduced-serum media.  
All measurements are relative to reference transcript Hprt. n=3 separate sets of 
differentiation, RNA isolation, reverse transcription, and analysis. (A) Desmin 
measurements were normalized to the non-transgenic C2C12 line, day 0. No 
significant differences by ANOVA. (B) Transgenic dystrophin measurements 
were normalized to the WT line, day 0.  ANOVA F<0.0001, WT and L54R 
statistically different than all non-trangenic samples. not significant within one 
sample type. (C-E) Western blot analysis of cell lines differentiated for 0, 3, and 7 
days. n=3 separate sets of differentiation, cell lysis, and Western blot analysis. 
(C) Representative western blots of desmin and transgenic dystrophin 
expression.  (D) Quantification of n=3 for Desmin protein. ANOVA F<0.001, 
p<0.05. (E) Quantification of n=3 for GFP-Dystrophin protein. ANOVA F<0.001, 
WT and L54R statistically different than all non-transgenic samples. n.s.= not 
significant within one sample type.  
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Figure 3.4:  Effect of missense mutations on heat shock pathway in cells. 
(A) Representative western blots for heat shock proteins in the 5 cell lines. (B) 
Quantification of n=3 separate cell lysis and Western blot analysis, all values 
normalized to non-transgenic sample.  For Hsp70, Hsp90, and Hsp90P, ANOVA 
was not significant.  For Hsp40, ANOVA F<0.01, ✱p<0.05 compared to WT.  For 
Hsp27P, ANOVA F<0.01, ✱p<0.05 compared to WT. 
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Figure 3.5:  Small molecule therapeutics screen to increase dystrophin 
protein levels    (A) Western blot analysis of osmolyte dosage treatments.  Cells 
were treated with varying concentrations of a given osmolyte (all in equal 
volumes of vehicle) for 24 hours.  Lysates were separated by electrophoresis and 
blotted with GFP antibody to detect the GFP-dystrophin fusion protein. C4 
antibody to detect pan actin was used as a loading control.  * These cells did not 
survive the given dosage.  (B) Western blot analysis of 18-hour heat shock 
activator dosage treatments.  Blots generated the same as A.  (C) Western blot 
analysis of 18-hour proteasome inhibitor dosage treatments.  Blots generated the 
same as A.  
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Figure 3.6:  Effect of positive hits from therapeutics screen on total 
dystrophin protein levels and ubiquitination  (A) Cells were treated with 40µM 
gedunin, 0.5µM bortezomib, or 0.5µM epoxomicin for 18 hours.  Cell lysates 
were separated by electrophoresis and blotted with GFP to detect the fusion 
protein, C4 to detect actin as a control, or ubiquitin antibody.  (B) Flow Cytometry 
of live cells. Cells were removed from culture and resuspended in PBS.  Cells 
were analyzed for GFP fluorescence while gated for forward and side scatter, 
and dead cells with the dye Sytox Red. Fluorescence levels of GFP were 
measured versus auto-fluorescence.  Percentages represent the number of cells 
that had GFP signal above negative control.  (C)  Flow Cytometry data in B 
displayed as histograms plots of the percentage of maximum cells with a given 
GFP fluorescent signal. 
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Figure 3.7:  Effect of positive hits from therapeutic screen on the heat 
shock pathway.  (A) Cells were treated with 40µM gedunin, 0.5µM bortezomib, 
or 0.5µM epoxomicin for 18 hours.  Lysates were analyzed by Western blot 
analysis for heat shock proteins. (B) Quantification of n=3 separate treatments, 
cell lysis, and western blot analysis represented in A. Hsp40 and Hsp90 for both 
L54R and L172H, and Hsp27P for L54R, ANOVA was not significant. For all 
other measurements, ANOVA F<0.05, ✱ p<0.05 compared to untreated control.  
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A Mouse Model of Missense  
Mutations in Dystrophin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunofluorescent microscopy was performed by John Olthoff.  Physiology 
assays for grip strength, whole body tension, activity after exercise, and serum 
CK activity were performed by Paul Chatterton while he was blinded to genotype.  
Eccentric contraction analysis was performed collaboratively with Dawn Lowe.  
All other cloning, mouse-line development, and analyses were performed by 
Dana Talsness.  
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Summary 
 Mutations in the DMD gene encoding for the protein dystrophin lead to 
Duchenne and Becker muscular dystrophy.  Several cases are reportedly caused 
by a missense mutation, which leads to a single amino acid substitution in the 
427 kDa dystrophin protein.  Two candidate missense mutations in the amino 
terminal first actin binding domain represent the spectrum of phenotypic severity 
seen in patients: L54R was found in a patient with the severe symptoms of 
Duchenne and L172H in a patient with the mild symptoms of Becker.  When 
previously studied in vitro, each mutation caused thermal instability of the full-
length protein.  Here we report the generation of two transgenic mouse models 
expressing full-length dystrophin with L54R or L172H mutations on a dystrophin-
null background.  Mutant protein levels were found to inversely correlate with the 
severity of disease first reported in the represented patients.  Histological 
analyses indicate that the L54R transgenic mouse line is just as severely affected 
as the dystrophin-null, while L172H has a more mild phenotype.  Physiological 
analyses indicate that both transgenic lines display symptoms of muscular 
dystrophy. Together, the new mouse models of missense mutations in dystrophin 
indicate the major cause of disease is the decreased abundance of dystrophin 
protein and will serve for future studies of therapeutics targeted towards 
missense genotypes.   
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Introduction 
 The most widely used animal model of Duchenne Muscular Dystrophy is 
the mdx mouse, a naturally occurring model due to a spontaneous mutation that 
was first discovered in a colony of C57BL/10 mice (Bulfield, 1984).  The mdx 
mouse presented with increased serum kinase levels and the phenotype 
segregated with the X-chromosome in a recessive manner.  Shortly thereafter it 
was discovered that the mdx mouse lacked the dystrophin protein seen in WT 
mice (Hoffman et al., 1987b) and had reduced levels of full-length dystrophin 
mRNA (Chamberlain et al., 1988).  These two molecular symptoms were very 
quickly ascribed to a nonsense mutation in exon 23 of the DMD gene (Sicinski et 
al., 1989), which definitively proved the mdx mouse was a genetic model for 
Duchenne Muscular Dystrophy. 
 The mdx mouse has been well characterized since its discovery.  In the 
same study that discovered the proteins of the dystrophin-glycoprotein complex 
(DGC) it was shown that they were decreased in the mdx mouse (Ervasti et al., 
1990).  Histological analyses have revealed smaller fiber size and increased 
central nucleation at 7 weeks of age compared to WT (Briguet et al., 2004), 
caused by the necrosis and then regeneration of muscle fibers (McGeachie et al., 
1993).  Physiological analyses show that mdx mice have mild symptoms 
compared to human DMD patients, but are distinguishable from WT mice for the 
parameters of forelimb grip strength, whole body tension, and force drop after 
eccentric contractions (Connolly et al., 2001; Carlson and Makiejus, 1990; Moens 
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et al., 1993), and these symptoms are ameliorated when dystrophin is 
transgenically over-expressed (Cox et al., 1993).  There are several hypotheses 
for their mild phenotype including up-regulation of the autosomal homolog 
utrophin, longer chromosome telomeres for increased regenerative capacity, and 
the simple fact that mice are quadrupedal and therefore less stress is put on limb 
muscles.  Despite its mild pathophysiology, the mdx mouse is a perfect genetic 
model of DMD patients with nonsense mutations; it has served and will continue 
to serve as a valuable tool for muscular dystrophy research. 
 A naturally occurring mutation that segregated with the X-chromosome 
was also found in a golden retriever dog that lacked protein expression of 
dystrophin (Cooper et al., 1988).  The causative mutation was later found to be a 
single nucleotide change in the 3’ splice site of intron 6 which results in out-of-
frame exclusion of exon 7 (Sharp et al., 1992).  The dogs are visibly dystrophic 
with abnormality of gait at nine to twelve weeks of age and moderate kyphosis by 
6 months of age (Valentine et al., 1988).  They develop muscle atrophy and 
subsequently have elevated serum CK levels.  The muscles of the GRMD dog 
are weaker and more susceptible to contraction-induced injury than a WT dog 
(Nguyen et al., 2002).  Overall the pathophysiology of the dogs more closely 
model the human DMD patients including decreased lifespan often as a result of 
cardiac or respiratory failure (reviewed in Kornegay et al. 2012).  While the 
GRMD dog more closely models human patients with loss-of-protein mutations in 
dystrophin there are obvious drawbacks such as the relative cost of housing a 
  90 
large animal with a longer lifespan. 
 Just within the last year the first animal model with a missense mutation in 
dystrophin was reported (Hollinger et al., 2013).  A line of pigs was discovered in 
Iowa that had a point mutation in exon 41 resulting in a full-length dystrophin 
protein with the amino acid change R1958W.  Phenotypically the R1958W pigs 
appear to most closely model mildly-affected BMD patients.  Western blot 
analysis revealed that dystrophin protein was expressed at only 30% of WT 
levels in diaphragm, psoas, and longissimus muscles, but localized correctly to 
the plasma membrane as assessed by immunofluorescent staining.  There was 
also decreased abundance of several DGC protein components consistent with 
DMD in humans.  Histologically there were necrotic lesions in the muscle and 
serum CK levels were 5-fold that of WT littermate controls.  While the R1958W 
pig will likely be a valuable tool in muscular dystrophy research and therapy 
development, there currently is no animal model that harbors a missense 
mutation specifically seen in any patients with Duchenne or Becker muscular 
dystrophy. 
 Here we report on the generation of two new mouse models expressing 
missense mutant dystrophins.  One mouse represents a severely affected DMD 
patient with mutation L54R while the other represents a more mildly affected 
patient with mutation L172H.  Molecular analysis of the two lines revealed that 
disease severity correlates with decreased levels of dystrophin protein which, 
corroborates results obtained with C2C12 cell lines modeling the same mutations 
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(Chapter 3).  Histological and physiological analyses further support the use of 
these two mouse lines as models of patients with Duchenne and Becker 
muscular dystrophy. 
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Materials and Methods 
Cloning and mouse generation 
Full-length mouse dystrophin cDNA (with missense mutations L54R and L172H) 
was subcloned into the Gateway system Entry vector as described in Chapter 2.  
The cDNA was then recombined into a vector containing the human skeletal 
alpha-actin (HSA) promoter and Vp1 intron that had been adapted to the 
Gateway system.  The expression cassette was cut out of the vector with 
restriction enzymes and sent to the University of Cincinnati Transgenic Mouse 
Core (L54R) or The Scripps Research Institute Mouse Genetics Core (L172H) for 
pronuclear injection into fertilized eggs.  Injected eggs were transplanted into 
pseudopregnant mice. Progeny were screened for the transgene by genomic 
PCR.  Transgenic mice were crossed onto the mdx background (mL54R and 
mL172H), and transgenic male progeny were analyzed.  All analyses were 
performed on mice 10-14 weeks of age. 
RT-qPCR 
Tissue was pulverized with mortar and pestle in liquid nitrogen.  RNA was 
isolated with the Aurum Total RNA Fatty and Fibrous Tissue (BioRad 732-6870).  
Total RNA was reverse transcribed into cDNA using the iScript™ Advanced 
cDNA Synthesis Kit (Biorad 170-8843).  cDNA was amplified using 
SsoAdvanced™ Universal SYBR® Green Supermix (Biorad 172-5270).  Primers 
for endogenous mouse dystrophin: Forward [TGGCAGATGATTTGGGCAGA] 
and Reverse [CCATGCGGGAATCAGGAGTT].  Primers for transgenic mouse 
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dystrophin: Forward [ACAATGTAGAAGGGTGGGCG] and Reverse 
[GCGTAGAATCGAGACGCGAGG].  Primers for intragenic mouse dystrophin: 
Forward [GCGCCAACACAAAGGACGCC] and Reverse 
[GCTTCAGCCTGGGGCTGCTC].  All measurements were relative to reference 
transcript Hprt: Forward [CCCTGGTTAAGCAGTACAGCCCC] and Reverse 
[GGCCTGTATCCAACACTTCGAGAGG]. Measurements were collected with the 
C1000 Touch Thermal Cycler (Biorad) and analyzed with the CFX Manager 
software (Biorad).  
Western blot analysis 
Tissue was pulverized with mortar and pestle in liquid nitrogen.  Tissue was then 
lysed with 1% SDS solution with added protease inhibitors [100nM Aprotonin, 
10mg/ml E-64, 100µM Leupeptin, 1mM PMSF, 1µg/ml Pepstatin] proportional to 
mass of the tissue pellet.  Protein concentration was measured by A280 
absorbance.  Equal concentrations of lysate were then separated by 
electrophoresed at 150V for 1 hour, then transferred to PVDF membrane at 
100V/0.7Amp for 1 hour.  Membranes were blocked in either [5% non-fat milk in 
phosphate buffered saline 0.1% Tween solution] or [5% Bovine Serum Albumin 
in tris buffered saline 0.1% Tween solution] depending on the primary antibody 
for 1 hour. Primary antibodies used were anti-Dys1 (Leica) at 1:100, anti-Dys2 
(Leica) at 1:100, anti-utrophin (Santa Cruz 8A4) at 1:100, anti-α-dystroglycan 
(Millipore 05-593) at 1:1000, anti-β-dystroglycan (vector labs VP-B205) at 1:100, 
anti-dystrobrevin (BD labs 610766) at 1:1000, anti-syntrophin (abcam 11425) at 
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1:1000, anti-pan actin C4 (Seven Hills Bioreagent LMAB-C4) at 1:5000, anti-
Desmin D93F5 (Cell Signaling 5332) at 1:1000, anti-Hsp40 C64B4 (Cell 
Signaling 4871) at 1:1000, anti-Hsp70 (Cell Signaling 4872) at 1:1000, anti-
Hsp90 (abcam 19021) at 1:1000, anti-Phosph-Hsp90α (Cell Signaling 3488) at 
1:1000, anti-Phospho-Hsp27 (Cell Signaling 9709) at 1:1000, and anti-Ubiquitin 
P4D1 (Cell Signaling 3936) at 1:1000.  Blots were then incubated in secondary 
antibodies anti-mouse or anti-rabbit IgG Dylight® 800 (Cell Signaling) at 1:10,000 
in blocking buffer.  Secondary antibody signal was visualized on Licor’s 
Odyssey® Infrared Imaging System and band density calculated with Odyssey 
Software v2.1.   
Immunofluorescent analysis 
Quadriceps and gastrocnemius muscles were dissected, frozen in melting 
isopentane, and embedded in optimum cutting temperature (OCT) compound 
submerged in liquid nitrogen.  Transverse sections of 10 µm were cut on a Leica 
CM3050 cryostat, air dried, and then fixed in 4% paraformaldehyde for 10 
minutes.  Sections were washed with PBS (150mM NaCl, 8 mM NaH2PO4, 42 
mM Na2HPO4) before being blocked with 5% goat serum/0.1% Triton X-100 for 
30 minutes.  A secondary block in Rodent Block M (Biocare Medical) was also 
performed for 30 minutes.  The sections were then incubated with primary 
antibodies overnight at 4°C.  Primary antibody dilutions were: NCL-Dys1 (1:20) 
(Leica), NCL-Dys2 (1:20) (Leica), Rb2 (1:20), Utrophin (1:50) (Santa Cruz), α-
Dystroglycan (1:50) (Millipore), β-Dystroglycan (1:50) (Vector Labs), Dystrobrevin 
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(BD Biosciences), nNOS (1:50) (Invitrogen), and Laminin (1:1000) (Sigma).  
Sections were then washed with PBS and incubated with Alexa Fluor 488- or 
Alexa Fluor 568-conjugated secondary antibodies (1:500 dilutions) for 30 minutes 
at 37°C.  Sections were washed with PBS and coverslips were applied with a 
drop of Prolong Gold antifade reagent with DAPI (Molecular Probes).  Images 
were collected on a Deltavision PersonalDV microscope equipped with a 
20x/0,75 objective (Applied Precision) and viewed with GIMP (GNU Image 
Manipulation Program) software. 
Histology and CNF count 
Cryosections were cut from the same blocks prepared for immunofluorescence at 
10µm thickness.  Sections were stained with hematoxylin and eosin-phloxine and 
imaged on Leica DM5500 microscope at 200x total magnification.  A total of at 
least 250 fibers were imaged from each muscle of each mouse and then centrally 
nucleated fibers (CNF) counted as a percentage of the total. 
Serum CK analysis 
Serum samples of the mice were collected by cheek bleed.  The samples were 
diluted 1:20 and then serum creatine kinase (CK) activity analyzed using CK DT 
slides (Ortho-Clinical Diagnostics) and a Kodak Ektachem DT 60 Analyzer.  CK 
activity is reported as U/L. 
Forelimb grip strength 
Mice were gripped at the base of their tail and positioned to grab the DFE series 
digital force gauge (Chatillon) with grip bar attachment. Once the mouse was 
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gripping the bar with both hands, the mouse was slowly with consistent force 
pulled perpendicularly away from the grip bar. Five trails were run per mouse and 
the average force was calculated. 
Whole body tension 
Mice were placed between parallel barriers, allowing only for forward movement.  
A slipknot suture was used to attach the base of the mouse tail to a fixed range 
force transducer (BioaPac Systems).  The tail of the mouse was then lightly 
pinched and the subsequent force evoked was measured. Five minute traces 
were collected and the top 5 peaks were averaged for each mouse and then 
normalized to body weight.  Protocol adapted from (Carlson and Makiejus, 1990). 
Activity after exercise 
Mice were acclimatized to the treadmill for 3 consecutive days, for 5 minutes at 
0m/min followed by 5 minutes at 9m/min at 0° decline.  On the fourth day, 
baseline pre-exercise activity was assessed for 30 minutes using laser-sensor 
activity cages (AccuScan Instruments Inc.).  Mice were then acclimatized to the 
treadmill for 5 minutes at 0m/min at 15° decline.  Without the use of electrical 
shock, mice were then encouraged to walk on the treadmill for 5 min at 5m/min 
followed by 10 minutes at 15m/min.  After exercise, activity was measured for 30 
minutes.  Total number of vertical episodes were counted and post-exercise 
activity reported as a percentage of the pre-exercise activity. 
Eccentric contraction analysis 
Mice were anesthetized with sodium pentobarbitoal and the extensor digitorum 
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longus (EDL) muscle dissected out.  Silk suture was used to attach the proximal 
tendon to a static structure and the distal tendon to a force transducer (Model 
300B-LR, Aurora Scientific).  The EDL was suspended in Ringer’s solution 
[120.5mM NaCl, 4.8mM KCl, 1.2mM MgSO4 1.2mM Na2HPO4, 20.4mM NaHCO3, 
10mM glucose, 10mM pyruvate, 1.5mM CaCl2], while 95% O2/5% CO2 was 
bubbled in.  Muscles were lengthened to an optimal tension and this set as the 
optimal length (L0).  Maximal twitch and tetanus were measured.  Then EDL 
muscle was subjected to an eccentric contraction protocol consisting of 5 
maximal tetanic stimulations (5.7ms pulses at 150Hz for 200 ms) while stretching 
from 95% to 105% of the L0 at 0.5 lengths per second.  Three minutes recovery 
was allowed between each eccentric contraction and maximum force recorded.  
Force production was plotted as percentage of the first contraction. 
Statistics 
All statistical calculation were performed with JMP® statistics software.  Data are 
presented as mean ± standard error of the mean.  To determine significance for 
all data with three or more groups, one-way ANOVA analysis was performed with 
α=0.05.  Upon significance of the ANOVA, the Tukey post hoc test was 
performed with all pairs of data at α=0.05. 
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Results 
 Transgenes were engineered harboring either L54R or L172H mutations 
in full-length dystrophin under the human skeletal α-actin (HSA) promoter which 
expresses almost exclusively in skeletal muscle.  These constructs were used to 
generate transgenic mice on a C57BL/6 background (Figure 4.1).  Transgenic 
L54R or L172H mice were crossed onto the mdx dystrophin-null mouse line to 
generate mice that expressed only mutant dystrophin (mL54R and mL172H).   
 Tibialis anterior (T.A.), gastrocnemius, and heart were analyzed by RT-
qPCR (Figure 4.2A,B).  Amplification of endogenous dystrophin transcript (top 
panel) reveals that mdx and transgenic lines on the mdx background have 
decreased levels due to nonsense mediated decay similar to prior reports.  As 
expected for transgenes driven by the HSA promoter, robust expression of 
mutant transcripts in both transgenic lines was only detected in skeletal muscle 
(middle panel).  Amplification of an intragenic region of dystrophin transcript 
(bottom panel) detected both endogenous and transgenic dystrophin for a side-
by-side comparison.  Statistical analyses show that both of the transgenic lines 
express dystrophin transcript at a level that is similar to WT mice.  Quantitative 
western blot analysis of skeletal muscle revealed that L54R and L172H mice 
expressed significantly less dystrophin compared to WT (Figure 4.2C-F).  mL54R 
mice expressed dystrophin protein at 7-9% that of WT and mL172H mice at 44%, 
both of which are statistically different from WT, correspond very closely to 
values from the transgenic myoblast lines in Chapter 3, and most importantly are 
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inversely correlated with disease severity of the patients with these mutations. 
 Mouse lines mL54R and mL172H were then analyzed for quantity of 
several components of the dystrophin glycoprotein complex (DGC) compared to 
WT and mdx mice (Figure 4.3A,B). Dys1 and Dys2 antibodies, with affinity to the 
central rod domain and C-terminus of dystrophin respectively, showed similar 
results and corroborate data in Figure 4.2.  Quantitiation reveals that utrophin 
levels in mdx were approximately 2-fold that of WT consistent with previous 
findings, and utrophin in the transgenic lines is similarly elevated.  The DGC 
components α-dystroglycan, β-dystroglycan, dystrobrevin, and nNOS, were 
significantly decreased in mdx, mL54R, and mL172H compared to WT, indicating 
both new transgenic lines still exhibit dystrophic DGC phenotypes.  The DGC 
component nNOS, however, shows an upward trend in abundance correlating to 
dystrophin protein levels in the mouse lines, and indeed mL172H expressed 
significantly more nNOS than mdx.   
 Localization of mutant dystrophin and members of the DGC were 
analyzed by immunofluorescence (Figure 4.3C).  Dystrophin was visibly absent 
in mdx as expected.  The mutant dystrophin that is present in the two transgenic 
lines appears to be localized correctly to the sarcolemma.  Utrophin in WT 
animals is present only at the myotendinus and neuromuscular junctions, and in 
mdx mice it is seen up-regulated and at the sarcolemma.  Transgenic lines also 
show utrophin present at the sarcolemma where it acts to mediate the loss of 
dystrophin.  The components of the DGC which were shown to be decreased in 
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the transgenic lines (Figure 4.3A,B) are still localizing to the sarcolemma, similar 
to previous reports of immunofluorescent DGC analysis in BMD patients 
(Arechavala-Gomeza et al., 2010; Anthony et al., 2011).  These results indicate 
that mutant dystrophin is present in the muscle at lower levels, but what is there 
is correctly localized to the membrane and is not forming aggregates within the 
cell. These data corroborate the data of Chapter 2, Figure 2.7D which showed 
full-length mutant dystrophin did not form aggregates in vitro.  Similarly, 
components of the DGC are not involved in protein aggregation and are correctly 
localized. 
 Histological analyses of WT, mdx, mL54R, and mL172H revealed signs of 
muscular dystrophy for both transgenic lines (Figure 4.4).  From representative 
images in Figure 4.4A, WT mice display uniform muscle fibers with nuclei 
localized at the periphery.  Mdx mice have fibers that are not uniform in size or 
shape and many fibers have centralized nuclei as has been reported many times 
before.  The mL54R line shows dystrophic features similar to mdx.  The mL172H 
is also dystrophic, but possibly to a lesser degree.  To quantify these 
observations, the fibers which are centrally-nucleated (CNF) were counted as a 
percentage of total fibers (Figure 4.4B).  The data reveal that mdx has 
significantly more CNFs than WT, as expected.  The mL54R and mL172H lines 
also had significantly increased CNFs over WT, but with lower average values 
than mdx.  Indeed mL172H quadriceps had significantly lower CNFs than both 
mdx and mL54R.  Across the four phenotypes, CNF values are proportional to 
  101 
the quantity of dystrophin protein measured (Figure 4.2) and the severity of 
patient muscular dystrophy symptoms modeled by each line.   
 As an indicator of sarcolemmal integrity, creatine kinase (CK) activity was 
measured in the serum from each line of mice (Figure 4.4C) and it was found that 
WT mice had almost no activity as expected.  Mdx had significantly elevated 
levels (11615 ± 1622) compared to WT.  Both mL54R and mL172H, however, 
had lower levels of CK activity (7848 ± 1840 and 4764 ± 2177 respectively), both 
of which were not statistically different from WT nor different from mdx.  The 
intermediate serum CK activity correlates inversely with dystrophin protein 
quantity and directly with disease severity.   
 We assessed our new transgenic mL5R and mL172H lines for several 
physiological impairments associated with muscular dystrophy in the mdx mouse, 
including grip strength, whole body tension, activity after exercise, and force loss 
during eccentric contraction (Figure 4.5). WT mice display an average grip 
strength of 32 mN/g (Figure 4.5A), while all three dystrophic lines (mdx, mL54R, 
mL172H) had significantly decreased grip strengths.  Whole body tension 
measures the force of both the proximal and distal muscles in all four limbs at 
once, with a WT mouse showing approximately 140mN/g of tension (Figure 
4.5B).  The mdx line gave a large range of variability, but each of the transgenic 
lines mL54R and mL172H were significantly decreased compared to WT.  The 
activity levels of mice were monitored before and after exercise (Figure 4.5C), 
and it was found that each of the dystrophic lines were significantly less active 
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than WT.  As a final assessment of physiological performance, extensor 
digitorum longus muscle was analyzed ex vivo for force loss after eccentric 
contraction (Figure 4.5D).  WT mice maintain the same level of force after 5 
eccentric contractions, while mdx, mL54R, and mL172H all drop to approximately 
20% of initial force by the 5th eccentric contraction.  A summary of all the ex vivo 
parameters measured (Table 4.1) shows that all three of the dystrophic models 
are significantly different than WT for specific force, change in specific force after 
eccentric contractions, and total force drop during eccentric contraction.  
Together, the physiological assays indicate both missense mutant lines are 
mildly dystrophic similar to mdx. 
 To determine if the missense mutations in dystrophin were stimulating the 
heat shock pathway, the relative abundance of the major heat shock proteins 
was measured by western blot analysis, similar to analysis of the myoblast 
models in Chapter 3.  Quantification from three separate sets of animals revealed 
no difference in the levels of Hsp40, Hsp70, Hsp90, or Hsp27P.  Hsp90P levels 
were almost undetectable.  While there was no significant increase, Hsp27P 
showed a upward trend for the mL54R line, indicating that there may be a slight 
perturbance to the heat shock pathway.  Relative increases, however, are 
nothing like the response from an actual heat shock that misfolds a large 
percentage of the proteome.  The lack of global heat shock response was similar 
to the missense myoblast model, and leaves the heat shock pathway as a 
possible therapeutic target for increasing dystrophin protein levels.  
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Discussion 
 Here we have reported on the generation of two transgenic mouse lines, 
representing severe DMD (L54R) and mild BMD (L172H) caused by missense 
mutations in dystrophin.  The transgenic transcript for each line is expressed at a 
level that is not different than endogenous WT dystrophin transcript, but the 
transgenic protein levels are at steady state levels of 7-9% for L54R and 43% for 
L172H.  Therefore dystrophin protein abundance inversely correlates with 
disease severity seen in the patients and we believe is the major mechanism of 
disease.  Molecular analysis of the dystrophin glycoprotein complex (DGC) 
components demonstrate that they are correctly localized but decreased in 
abundance.  Histological analysis of the two transgenic lines indicates that 
muscle degeneration and regeneration occurs in both L54R and L172H, with 
L54R being more severely affected and closer to mdx phenotype.  Physiological 
analyses demonstrate that despite expression of some dystrophin protein, both 
of the missense mutant lines display symptoms of muscular dystrophy. 
 The original reports of missense mutations L54R and L172H were more 
than a decade apart from each other and therefore could not be compared side 
by side (Prior et al., 1993; Hamed et al., 2005).  While the physiology of the 
patients was well reported the molecular analysis was minimal, with both groups 
estimating that the patient expressed 20% dystrophin levels.  Here we have 
demonstrated in a side-by-side manner in our mouse models that dystrophin 
protein levels are much lower in the severely affected L54R mutation.  These 
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results correlate with the level of protein seen in the cell culture models from 
Chapter 3, and these decreased levels can be ascribed to the degree of in vitro 
misfolding as seen by differential scanning fluorimetry in Chapter 2.  It is 
important to note that there is thus far no evidence of aggregation, but rather only 
elimination of the mutant dystrophin protein.  This evidence differentiates 
missense DMD/BMD from protein aggregation diseases such as Huntington’s 
and Alzheimer’s, and offers hope that upregulating the amount of dystrophin 
protein could alleviate symptoms of disease. 
  Several reports have examined the relationship between dystrophin 
protein expression levels and disease phenotype.  Two separate studies of 
transgenic mice expressing either full-length or mini-dystrophin have shown that 
serum CK levels and CNF percentages inversely correlate with dystrophin 
protein levels, similar to our two transgenic lines (Wells et al., 1995; Phelps et al., 
1995).  Unlike our lines, however, both groups found that expression at or above 
20% of controls was enough to ameliorate most dystrophic phenotypes.  The 
mL172H line expresses dystrophin at approximately 40% that of control but is not 
rescued for any of the physiological assays, indicating the missense mutations 
may be affecting dystrophin functionality.  Analysis of two non-transgenic mouse 
models, one harboring a splice-site mutation in dystrophin and the other with 
non-random X-inactivation, have led the authors to conclude that only 5% of WT 
dystrophin is enough to partially protect it from some dystrophic phenotypes (Li et 
al., 2008a; van Putten et al., 2012).  Our mL54R line expresses >5% dystrophin 
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protein and shows no significant differences compared to mdx, again suggesting 
the amino acid change may decrease the functionality of the dystrophin protein 
present at steady-state levels.  Indeed perturbations such as the 4-fold decrease 
in actin-binding affinity caused by L54R (Henderson et al., 2010) may have a 
large effect when <10% of normal protein levels are present.  To determine 
whether missense mutations decrease the in vivo functionality of dystrophin, 
future studies will aim to increase mutant dystrophin levels with small molecule 
treatments.  If an up-regulation of mutant dystrophin does not improve 
physiological performance then the missense mutations are likely impairing 
dystrophin function. 
 The two dystrophin low-expression mouse models described above have 
been crossed to mice lacking both utrophin and dystrophin (mdx/utr-/-), which 
then showed even greater separation of phenotype based on percentage of 
dystrophin protein (Li et al., 2010b; van Putten et al., 2013).  Given that the mdx 
model itself has mild physiological symptoms compared to DMD patients with the 
same type of mutation largely due to compensatory utrophin upregulation, it may 
be that subtle changes in phenotype of mL54R and mL172H lines compared to 
mdx are being masked.  Therefore future studies will cross each line to the 
mdx/utr-/- mouse line.  If a significant difference in physiological assays is seen 
between m/utr-/-/L54R and m/utr-/-/L172H compared to mdx/utr-/- then utrophin is 
likely masking subtle phenotypic differences caused by the missense mutations.    
 In summary, mouse lines mL54R and mL172H demonstrate that missense 
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mutations decrease dystrophin protein levels similar to values seen in myoblast 
cell models and proportional to disease severity seen in patients.  It is our hope 
that these models will aid in the development of personalized therapeutics for 
DMD and BMD patients with missense mutations. 
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Figures 
 
 
 
 
Figure 4.1: Expression construct and experimental concept.  Full-length, 
mouse dystrophin cDNA was subcloned into a vector containing a human 
skeletal α-actin (HSA) promoter and Vp1 intron.  The fragment was pronuclear 
injected into fertilized eggs and transplanted into a pseudopregnant mouse.  
Male founders (L54R and L172H) were crossed to female mdx. Male offspring 
express the transgene on an mdx background (mL54R and mL172H).  
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Figure 4.2: RNA and protein expression levels in transgenic mouse lines.  
(A) and (B) RT-qPCR analysis for mouse lines L54R and L172H respectively.  
Top panel shows amplification within the 3’UTR of endogenous mouse 
dystrophin. Middle panel shows amplification within the 3’UTR of the transgenic 
dystrophin. Bottom panel shows amplification within the coding region of 
dystrophin, amplifying both endogenous and transgenic dystrophin.  ANOVA 
analysis of the intragene amplifications were F<0.05 for both lines. Post hoc 
analysis between WT and transgenic were n.s. (not significant).  (C) and (D) 
Representative western blot analyses of mouse lines L54R and L172H 
respectively.  (E) and (F) Quantification of western blots from n=3 separate sets 
of mice.  ANOVA analysis for both lines gave F<0.05.  Post hoc analysis ✱p<0.05 
compared to WT.    
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Figure 4.3: Expression levels and localization of components in the 
Dystrophin Glycoprotein Complex.  (A-C) Utr = utrophin, α-DG = alpha-
dystroglycan, β-DG = beta-dystroglycan, DB = dystrobrevin, Syn = syntrophin, 
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nNOS = neuronal nitric oxide synthase.  (A) Representative western blot 
analyses for several components of the DGC in tibialis anterior muscle, including 
two different antibodies for dystrophin corroborating results found in Figure 4.2.  
(B) Quantification of western blots for n=3 separate sets of mice.  Values are all 
normalized to WT for each blot. ANOVA with significance of F<0.05 were 
analyzed with post hoc statistics.  ✱p<0.05 compared to WT.  #p<0.05 between 
mdx and L172H.  (C) Immunofluorescent analysis of components of the DGC in 
quadriceps muscle. Scale bar = 20µm. 
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Figure 4.4:  Fiber morphology and permeability. (A) Representative 
quadriceps muscle sections stained with H&E and imaged at 200x magnification.  
Scale bar = 20µm.  (B) Quantification of centrally nucleated fibers (CNF) as a 
percentage of the total fibers.  A minimum of 250 fibers were counted for each 
mouse.  ANOVA analysis was significant at F<0.0001. Post hoc analysis gave 
✱p<0.05 for WT versus all disease models, and for mL172H versus mdx and 
mL54R.  (C) Serum creatine kinase (CK) activity from cheek bleeds of individual 
mice.  ANOVA analysis was significant at F<0.01.  Post-hoc analysis gave 
✱p<0.01 for WT versus mdx.  Both transgenics were not statistically different 
from WT.   
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Figure 4.5: Physiology of transgenic mouse models.  (A) Forelimb grip 
strength analysis.  Individual points are an average of 5 trials for each mouse.  
ANOVA was significant at F<0.001.  Post hoc analysis gave ✱p<0.005 compared 
to WT.  (B) Whole body tension analysis.  Individual points are an average of 5 
trials for each mouse.  ANOVA was significant at F<0.01.  Post hoc analysis gave 
✱p<0.05 compared to WT.  (C) Activity after exercise analysis.  ANOVA was 
significant at F<0.005.  Post hoc analysis gave ✱p<0.05 compared to WT.  (D) Ex 
vivo EDL force measurement during eccentric contraction.  For ECC 2-5, all three 
dystrophic models were significantly different than WT.   
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Figure 4.6: Effect of missense mutations on the heat shock pathway of the 
mice.  (A) Representative western blots of heat shock proteins in each of the 
mouse lines from tibialis anterior muscle.  Hsp90P was barely detectable.  (B) 
Quantification of n=3 sets of mice.  ANOVA analysis for each protein was not 
significant. 
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 WT mdx mL54R mL172H 
EDL mass (mg) 12.8 ± 0.4 16.3 ± 1.5 14.2 ± 0.8 13.5 ± 0.7 
L0 (mm) 13.3 ± 0.2 12.3 ± 0.1 12.4 ± 0.1 12.9 ± 0.1 
CSA (cm2) 0.021 ±0.001 0.029 ± 0.003 0.025 ± 0.001 0.022 ± 0.001 
passive stiffness (N/m) 13.9 ± 0.9 16.8 ± 1.0 14.2 ± 0.6 15.8 ± 0.7 
active stiffness (N/m) 755.7 ± 36.2 720.7 ± 31.8 695.4 ± 38.2 785.5 ± 20.6 
P0 (mN) 448.5 ± 8.8 416.8 ± 31.5 414.7 ± 29.5 393.2 ± 34.7 
specific P0 (N/cm2) 21.8 ± 0.5 14.8 ± 0.8 # 16.9 ± 0.5 # 17.4 ± 0.9 # 
ΔP0 (%) 11.1 ± 3.1 82.8 ± 5.4 # 75.8 ± 5.8 # 73.6 ± 4.4 # 
force drop (%) 2.1 75.1 ± 4.3 # 69.5 ± 5.5 # 65.7 ± 2.1 # 
 
Table 4.1:  Summary of ex vivo EDL parameters.  For measurements of 
specific force, change in specific force, and force drop during eccentric 
contractions ANOVA was significant at F<0.01.  Post hoc analysis gave #p<0.05 
compared to WT. 
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Conclusions and Discussion 
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Thesis Findings 
 Duchenne and Becker muscular dystrophy have been described clinically 
since the mid-1800’s, and in the late 1980’s it was discovered that the diseases 
were due to mutations in a 2.4Mb gene on the X-chromosome encoding the 
427kDa protein dystrophin (Duchenne, 1861; Koenig et al., 1988, 1987).  
Causative mutations vary in type from exonic deletions and insertions to 
nonsense and splice-site mutations (Aartsma-Rus et al., 2006).  A small, but 
growing number of patients harbor missense mutations in the DMD gene and 
experience a wide range of muscular dystrophy severity (Prior et al., 1993; 
Hamed et al., 2005).  The aims of this thesis were to compare the in vitro effect 
of missense mutations in the various domains of dystrophin, determine the 
cellular consequences of missense mutant dystrophin, and to generate animal 
models of severe and mild forms of muscular dystrophy caused by missense 
mutations.   
 Several studies have examined the effect of missense mutations on 
peptide fragments of dystrophin in vitro (Singh et al., 2010; Legardinier et al., 
2009; Ishikawa-Sakurai et al., 2004), and previous work in our lab has 
discovered that missense mutations in the N-terminal ABD1 cause thermal 
instability of full-length dystrophin protein in vitro (Henderson et al., 2010).  In 
chapter 2, we reported that missense mutations in the spectrin-like repeats of the 
central rod domain cause no visible change in protein stability when expressed in 
Dp260 or full-length dystrophin in vitro.  In contrast, several missense mutations 
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in the cysteine-rich and C-terminal domain caused decreased solubility and 
expression.  Finally side-by-side comparison of mutations in the three major 
domains of dystrophin revealed that only mutations in the N-terminal domain 
perturbed the tertiary structure.  The in vitro model of missense mutations in 
dystrophin provided understanding of the biochemical effects a mutation could 
have on the protein and lead to hypotheses about the fate of mutant dystrophin in 
the cell. 
 The study of transgenic dystrophin in a cell culture system has been 
limited to a few reports that expressed small fragment peptides, including a 
report of missense mutations in the β-dystroglycan binding domain, two of which 
decreased the levels of the dystrophin peptide and one which ablated 
dystroglycan binding (Vulin et al., 2014).  In chapter 3, we have reported on the 
generation of four transgenic myoblast cell lines stably expressing full-length 
dystrophin.  The two lines expressing disease-causing missense mutations, 
L54R and L172H, express protein at a steady-state level that is decreased 
relative to WT and inversely correlates with muscular dystrophy severity of the 
modeled patients.  We demonstrated that mutant dystrophin protein could be 
increased with the use of small molecule osmolytes, heat shock activators, or 
proteasome inhibitors; indicating the mutant protein is unstable, targeted by the 
heat shock pathway, and degraded by the proteasome.  The myoblast lines offer 
insight into the molecular mechanism of muscular dystrophy when caused by 
missense mutations and can serve as a platform for discovery of more 
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personalized medicine approaches.   
 The mdx mouse has served as a well-studied model of nonsense 
mutations in dystrophin (Sicinski et al., 1989), and recently a pig was reported as 
a model of missense mutations in dystrophin (Hollinger et al., 2013).  In chapter 4 
we reported the generation of two new mouse models, transgenically expressing 
full-length dystrophin with missense mutations L54R and L172H.  Both mL54R 
and mL172H lines express dystrophin transcript at levels similar to endogenous 
WT dystrophin, yet have steady-state protein levels of ~10% and ~40% of WT 
respectively.  Decreased protein levels suggest the missense mutations cause 
misfolding and/or instability which targets the dystrophin protein for degradation 
in the muscle to a degree that is proportional to disease severity seen in the 
modeled patients.  Histological analyses of serum CK and CNF percentage also 
correlate with dystrophin levels.  Interestingly, physiological assessment of 
mL54R and mL172H mice reveals no difference compared to mdx while other 
studies of low dystrophin expression show phenotypic improvements, which 
leads to the hypothesis that either the missense mutations are somehow 
perturbing the functionality of the dystrophin protein that is not degraded or the 
mild phenotype of the mdx mouse is masking subtly differences in phenotype. 
Mouse lines mL54R and mL172H corroborate the molecular mechanism of 
disease discovered in the myoblast cell lines and further characterization will 
hopefully lead to novel avenues of treatment for DMD and BMD caused by 
missense mutations.  
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Personalized Therapeutics for Missense Mutations in Dystrophin 
 While there are currently efforts to treat nonsense mutations with stop 
codon read-through drugs and insertion/deletions with exon skipping, there is 
currently no personalized therapeutic aimed at missense mutations in dystrophin.  
In chapter 3 we demonstrated that there are at least three categories of small 
molecules that were able to increase the steady-state level of missense mutant 
protein: osmolytes, heat shock activators, and proteasome inhibitors.  The 
osmolyte betaine was found to stabilize mutant dystrophin at very high 
concentrations.  Therefore it could not be used as a stand alone treatment, but 
has the potential to be used in combination with other therapies as a small 
contributor to dystrophin stability.  The heat shock activator gedunin was found at 
moderate concentrations of less than 100µM to restore mutant dystrophin to WT 
levels.  While 40-80µM is likely too high of a dosage to be used as a therapeutic, 
gedunin serves as a proof-of-principle for the use of heat shock activators.  
Future high-throughput screens may find one of sufficient efficacy to be given at 
a tolerated dose for the treatment of missense mutations.   
 The most successful category of small molecules for increasing mutant 
dystrophin levels was the proteasome inhibitors.  Each of the tested proteasome 
inhibitors restored mutant dystrophin to WT levels at concentrations less than 
10µM, which is a reasonable dosage for patient administration.  Indeed, patients 
are currently receiving treatments of proteasome inhibitors such as bortezomib 
and epoxomicin-derivative carfilzomib for treatment of multiple myeloma and 
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other cancers (Kisselev et al., 2012).  Cancer treatment is intended to be acute 
given that once the cancer is gone, treatment is terminated.  If proteasome 
inhibitors were used to increase dystrophin protein levels in patients with 
missense mutations, however, treatment would need to be continued for the 
entire life of the patient.  Further work is needed to determine if chronic 
proteasome inhibition could be tolerated, but it still offers a promising new route 
of therapy. 
 While inhibiting the proteasome is an effective way to block the 
degradation of dystrophin, it also inhibits the degradation of all other proteins in 
the cell thereby interfering with the normal cell metabolism.  If, however, the 
upstream ubiquitination ligases specific to dystrophin were inhibited, the cell 
could maintain normal function.  Similarly, the cancer biology field has been 
developing several proteasome inhibitors for treatment of multiple myeloma 
(Kumar et al., 2008), yet recently have begun to target the cancer specific E3 
ligases responsible for ubiquitination of p53 and c-Myc (reviewed in Weathington 
& Mallampalli, 2014).  Determining the specific E1-E2-E3 cascade for a given 
substrate is a difficult task given that there are approximately 40 E2 conjugating 
enzymes and over 600 E3 ligases (Deshaies and Joazeiro, 2009; Li et al., 
2008b).  The missense cell lines that we have generated are the first model 
system that could allow for the efficient identification of the E1, E2, and E3 
enzymes responsible for ubiquitination and subsequent degradation of 
dystrophin.  Small molecule inhibitors of the specific E3 ligase could then be 
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used as a highly targeted form of therapy for persons with missense mutations in 
dystrophin. 
 Whether heat shock activators, proteasome inhibitors, or ubiquitin ligase 
inhibitors, potential therapeutics will need to be researched extensively in pre-
clinical studies.  The two transgenic mouse lines expressing missense mutated 
dystrophin reported in chapter 4 can serve as models for such pre-clinical 
investigations.  A candidate small molecule would be administered to the mice to 
determine proper dosage, dosing schedule, degree of phenotype improvement, 
side effects, etc.  An ideal therapeutic would be well tolerated by the mice, cause 
large increases in dystrophin protein levels, and rescue the dystrophic 
phenotypes of the mice.  Small molecules which show promise in the mouse 
models could then be pre-clinically studied in the pig model of missense 
mutations in dystrophin. 
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Applications to Other Mutations and Therapies 
 Missense mutations in dystrophin are rare, estimated to occur in less than 
10% of DMD and BMD patients (Flanigan et al., 2009), yet the understanding 
gained from missense mutation models has the potential to aide in the treatment 
of patients with other types of mutations.  BMD is often the result of in-frame 
deletions or insertions, resulting in internally-truncated dystrophin protein.  In 
addition to potentially lacking functional domains, internally-truncated dystrophin 
has been shown to be thermally unstable in vitro (Henderson et al., 2011).  
Protein instability manifests as decreased protein expression seen in BMD 
patients (Anthony et al., 2011), similar to the results seen here for missense 
mutations.  If a therapeutic is discovered that increases the levels of missense 
mutant dystrophin and phenotypic improvements are observed, the same therapy 
could potentially be applied to BMD insertion and deletion patients.   
 In addition to missense mutation therapies expanding to other types of 
mutations, they may be relevant as an “add-on” to other personalized treatments.  
Exon-skipping is a promising gene therapy aimed at DMD patients with out-of-
frame deletions or insertions (Goemans et al., 2011), with effective treatment 
resulting in in-frame deletions of the transcript.  The restored protein would 
therefore mimic BMD patient protein described above and potentially benefit from 
the same treatment that decreases degradation due to protein misfolding.  
Similarly, gene replacement strategies currently rely on internally-truncated 
dystrophin sequences that are small enough to be encoded within AAV 
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constructs, and would likely result in expression of dystrophin protein at levels 
below WT due to misfolding and degradation.  Finally, stop codon read-through 
drugs are currently in clinical trials to treat DMD patients with nonsense 
mutations in dystrophin (Peltz et al., 2013).  Successful read-through would result 
in the incorporation of a random amino acid effectively turning a nonsense 
mutation into a phenotypic missense mutation, making the work of this thesis and 
future missense mutation studies directly applicable.   
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Continuing Study 
 The evidence from the cell culture models of Chapter 3 suggest that 
mutant dystrophin is being degraded by the proteasome, and future studies will 
determine if proteasome degradation is also occurring in the mouse models in 
Chapter 4.  Efforts are currently underway to treat mL54R and mL172H mice with 
proteasome inhibitors, which lead to several questions about the consequences 
of increasing the levels of these mutant dystrophins.  For instance, does blocking 
their degradation by the proteasome now cause them to aggregate or do they 
function normally?  And what percentage of WT dystrophin would be needed to 
ameliorate symptoms?  If treatment increases dystrophin protein levels, we plan 
to assess the mice for improved physiological performance by eccentric 
contraction force drop measurements.  An improvement in maximal force output 
after 5 serial eccentric contractions compared to mdx would indicate two things:  
1) the main disease mechanism of missense mutations is decreasing the amount 
of dystrophin protein and 2) increasing mutant dystrophin is a viable treatment 
option to ameliorate phenotypes of disease.  A lack of improvement may indicate 
the increased mutant dystrophin is aggregating, therefore muscle pathology and 
protein aggregation will be evaluated histologically in collaboration with Dr. 
Michael Lawlor using a panel of histochemical stains, including H&E, Gomori 
trichrome, NADH, and congo red stains.  Patterns indicative of aggregation will 
include both visible aggregates of protein and/or evidence of organelle 
displacement as a result of abnormal protein localization. 
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 In addition to proteasome inhibition, we plan to cross the mL54R and 
mL172H lines to the utrophin- and dystrophin-null mouse, mdx/utr-/- as discussed 
in chapter 4.  If the molecular, histological, and physiological analyses of the 
resulting m/utr-/-/L54R and m/utr-/-/L172H mice show less dystrophic phenotypes 
compared to non-transgenic littermate controls then utrophin was likely masking 
subtle differences in phenotype caused by the missense mutations.  These mice 
would be more accurate models of the original patients diagnosed with DMD 
(L54R) and BMD (L172H), just as the mdx/utr-/- mouse itself is a better 
phenotypic model of DMD patients with nonsense mutations.  If, alternatively, 
physiological phenotypes are still comparable between transgenic and non-
transgenic littermates, then the missense mutations are likely causing a decrease 
in the functionality of dystrophin in addition to causing a decrease in the steady-
state levels of the protein.   
 As mentioned in the personalized therapeutics section, identification of the 
E2 and E3 ligases responsible for the ubiquitination of misfolded dystrophin 
would possibly allow for highly specific inhibition of dystrophin degradation 
without inhibiting the degradation of all other proteins in the cell.  Efforts are 
currently underway to systematically knock-down E1, E2, and E3 ubiquitin 
ligases in L54R myoblasts with commercially available 96-well siRNA arrays.  
Initially the set of E1 activating enzymes and E2 conjugating enzymes will be 
assessed and then E3 ligases.  Positive hits detected as increased GFP 
fluorescence by flow cytometry (Figure 3.6B) will be validated with larger scale 
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cell culture knock-down and western blot analysis for full-length dystrophin.  If an 
E3 ligase is identified, the literature will be searched for an existing knockout 
mouse model or a knock-out will be generated.  The E3-null mouse could then be 
crossed to the mL54R and mL172H mice and progeny assayed for mutant 
dystrophin protein abundance and muscular dystrophy phenotypes.   
 In summary, the models of missense mutations in dystrophin reported in 
this thesis will continue to be useful for further understanding the mechanism of 
disease and for developing personalized therapy options for patients with 
missense mutations.   
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